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Surgical repair of torn rotator cuff tendons have a high rate of failure and does not 
address the underlying pathophysiology. Tissue engineering strategies, employing the use 
of multipotent progenitor cells or growth factors, represent potential therapies to improve 
the outcome of rotator cuff surgery. The use of glycosaminoglycan-based biomaterials in 
these therapies may enhance the effectiveness of cell and growth factor delivery 
techniques. Furthermore, understanding the cellular and molecular mediators in tendon 
overuse can help elucidate the causes of tendon degeneration. Thus the overall goals of 
this dissertation were to 1) develop heparin-based biomaterials to enhance cell pre-culture 
and maintain growth factor bioactivity and 2) characterize the histological and enzymatic 
changes in a supraspinatus tendon overuse model. 
To investigate the use of heparin in enhancing dynamic signaling, mesenchymal 
stem cells (MSCs) were encapsulated in heparin-containing hydrogels and evaluated for 
differentiation markers when cocultured with a small population of differentiated cells. 
To probe the effect of sulfation of heparin on the interactions with protein, selectively 
desulfated heparin species were synthesized and evaluated for their ability to bind and 
protect proteins. Finally, to develop a tendon overuse model that can become a test bed 
for testing future targeted therapeutics, an animal model was evaluated for tissue damage 
and protease activity. Together these studies represent a multi-pronged approach to 
understanding how tendon tissues become degenerative and for developing technologies 
to improve the biological fixation of tendon to bone in order to reduce the need for 






Rotator cuff disease is a complex shoulder condition that can range from acute 
tendon tears to chronic tendinopathy. The supraspinatus tendon, which participates in 
arm abduction, is commonly afflicted due to highly repetitive work and can result in 
shoulder pain and dysfunction [1]. Due to the relative avascularity and low celluarity of 
tendon tissue, intrinsic healing may not be adequate and surgical intervention may be 
necessary [2]. Over 200,000 Americans per year require shoulder surgery to repair the 
rotator cuff, with the volume of repairs likely increasing as the current population ages 
[3]. While surgery can alleviate symptomatic shoulder dysfunction, revision surgeries 
can be as high as 57% and do not address the underlying pathophysiology [4]. 
Commonly cited causes for revision surgeries include tendons pulling out of sutures and 
poor tendon-bone integration, particularly with degenerative tendon [5-8].  
Recapitulation of the natural interface between tendon and bone would improve 
tissue integration after tendon reattachment surgery [7]. This interface of tendon to 
uncalcified fibrocartilage to calcified fibrocartilage before inserting to bone allows for 
stress dissipation at intact tendon attachment sites [9]. Tissue engineering approaches 
have investigated the development of phasic tissues by graded material, ligand, or cell 
incorporation [10-12]. However, after tendon reattachment, it is important to quickly 
stabilize the tendon-bone interface, minimize the amount of granular tissue that forms 
between tendon and bone, and accelerate the early stages of healing in order to populate 
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the interface with desired cells. Tissue engineering strategies frequently employ the use 
of multipotent progenitor cells to either rebuild the tissue environment or secrete 
paracrine factors that elicit endogenous cell responses. Mesenchymal stem cells (MSCs) 
are multipotent progenitor cells found in the adult bone marrow, that are capable of 
differentiating into bone, cartilage, and fibrous tissues [13]. Delivery of MSCs to 
transected tendons have shown acceleration of early healing responses [14]. These cells 
can be sensitive to paracrine signals, as MSCs cocultured with differentiated cell types 
can become differentiated and lead a more established in vivo phenotype [15, 16].  
Delivery of bioactive factors, such as bone morphogenetic protein (BMP)-2 is 
another avenue to improve integration of tendon to bone [17, 18]. BMP-2 has the ability 
to induce cell migration of osteoblasts and mesenchymal progenitor cells and encourage 
mesenchymal stem cell differentiation into an osteochondral or osteogenic lineage [19-
24]. These cell types are available during a typical rotator cuff surgical procedure, 
particularly if the tendon is reattached at a bony trough [25, 26]. BMP-2 is currently 
approved by the FDA for use in spinal fusion, however, use of supraphysiologic doses 
and a collagen carrier that has weak affinity for BMP-2 increases cost of treatment and 
places patients at risk of side-effects due to off-site effects [18, 27-29]. A suitable 
delivery system that can reduce the high dosage of BMP-2 by limiting burst release and 
protecting the bioactivity of BMP-2 is desired.   
  Finally, understanding what cellular and molecular mediators are involved in 
tendon overuse can help elucidate the causes for degenerative tendon. While past injury 
models include tendon transection and collagenase injection, mechanical overuse of 
tendon is more physiologically relevant and may provide insight into the mechanisms of 
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chronic tendinopathy. Additionally, use of an animal model that can yield repeatable 
results will be essential in becoming a test bed for testing targeted therapeutics, 
including growth factor delivery systems and cellular therapies. A multi-pronged 
approach to understanding how tendon tissue become degenerative and developing 
technologies to improve the biological fixation of tendon to bone will help develop 
therapies that prevent shoulder dysfunction and the need for revision treatments.  
 
1.2 Research Objectives 
 The objective of this research was to understand protein interactions with heparin 
and heparin derivatives as a tissue engineering approach to eventually treat tendon 
overuse injuries. This was achieved by 2 parallel focus areas: 1) to understand the 
effects of heparin in crosslinked and soluble forms and 2) to evaluate an inbred rat 
tendon overuse model. Heparin is a highly sulfated, linear glycosaminoglycan (GAG) 
with important clinical roles such as an anti-coagulant, and in biologic roles such as in 
stabilizing growth factor-receptor complexes [30, 31]. Its high sulfation level and 
various biological roles render it an attractive biomaterial for affinity delivery systems. 
 A heparin-containing hydrogel system was developed to encapsulate MSCs in 
order to evaluate the effect on osteogenic marker expression during coculture with 
monolayers of osteoblasts. Heparin was chemically modified to allow covalent 
attachment within a synthetic hydrogel network. Upon finding that diffusion within 
heparin-containing hydrogels could be reduced by higher sulfation level, modulation of 
overall negative charge and level of protein interaction was achieved by chemically 
desulfating heparin. The high negative charge density of heparin is known to bind 
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positively-charged proteins electrostatically as well as bind specific proteins with 
heparin-binding sites. The role of heparin sulfation on maintaining BMP-2 bioactivity 
was explored by heat treating BMP-2 with and without heparin derivatives and assessing 
the growth factor bioactivity. While improving tendon-bone integration is a motivation 
in developing effective tissue engineered constructs that can address a clinical need, it is 
also important to evaluate an injury model in order to prevent tendon rupture. A 
shoulder overuse protocol was adapted for an inbred strain of rat to determine 
histological and enzymatic events that occur in overused tendon. This overuse model is 
physiologically relevant and can elucidate cellular changes that precede chronic 
tendinopathy and tendon rupture. The central hypotheses of this research are that 1) 
engineered heparin-based materials can enhance signaling to MSCs from sequestered 
factors and can preserve protein bioactivity even after chemical desulfation and 2) a 
tendon overuse model in an inbred strain of rat will show tissue damage by overuse that 
is accompanied by increased activity of proteases. These hypotheses were explored 
through the following three specific aims:     
 
Hypothesis I: MSCs encapsulated in hydrogels containing increasing amounts of 
covalently-crosslinked heparin will produce higher levels of osteogenic markers when 
co-cultured with monolayers of osteoblasts.  
Specific Aim I: Determine the ability of heparin-containing hydrogels to amplify 
alkaline phosphatase activity (ALP) and mineralization of a large population of MSCs 
with a small population of osteoblasts.  
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 Coculture systems have been utilized to enhance proliferation of cells of interest 
and differentiate stem cells with a population of differentiated cells [32, 33]. Heparin-
containing materials have been shown to sequester and protect proteins from the 
environment, and may be beneficial in a coculture setting by maintaining active soluble 
signals within the hydrogel [34]. Coculture systems with MSCs have previously been 
studied with various differentiated cell types from orthopaedic tissues and the following 
study uses osteoblasts as a model differentiated cell type to study the effects of the 
heparin-containng hydrogels [35, 36]. Other differentiated cells found at the insertion 
site of tendon such as chondrocytes and tenocytes may be adopted for use in this system.  
Heparin was functionalized to allow covalent incorporation into PEG-based 
hydrogels. MSCs were encapsulated in hydrogels of increasing heparin content and then 
cocultured with monolayers of osteoblasts or MSCs in the absence of dexamethasone. 
Acellular hydrogels were cocultured in parallel to determine cell-mediated effects. 
Alkaline phosphatase (ALP) activity, calcium accumulation, and von Kossa staining 
evaluated the effect of coculture and heparin on MSCs within the hydrogels. To examine 
the interaction of positively-charged proteins with heparin-containing hydrogels, 
solutions of fluorescently-tagged model proteins were incubated with acellular 
hydrogels to examine the distribution of protein within the hydrogel after 24 hours.   
 
Hypothesis II: The ability of heparin to protect BMP-2 against thermal stress will 
decrease as the sulfation level of heparin derivatives decrease, due to loss of negative 
charge density.   
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Specific Aim II: Chemically desulfate heparin and determine BMP-2 bioactivity after 
heat treatment when complexed with heparin and desulfated derivatives of heparin. 
Heparin is used as an anti-coagulant therapy, and in order to reduce off-site 
effects, inactivation of the anti-coagulation feature of heparin while maintaining its 
protective abilities is necessary. This has been explored by chemically removing sulfates 
from heparin [37]. Much research has gone into characterizing the interaction of 
fibroblast growth factor (FGF)-1 and -2 with heparin, in which heparin can protect FGF-
1 and -2 from denaturing environments in a heparin sulfation-dependent manner [38].  
Less is known about how BMP-2, a heparin-binding protein with a flexible heparin-
binding domain, can be protected by heparin molecules. Furthermore, since the high 
negative charge density of heparin can affect diffusion of charged molecules within a 
hydrogel, heparin desulfation would provide a library of less charged materials for 
future applications.    
Selectively desulfated heparin derivatives were prepared and characterized by 
change in chain length, proton nuclear magnetic resonance and overall sulfation level. E. 
coli-derived BMP-2 was heat-treated for a range of times, either alone or incubated with 
heparin derivatives. The BMP-2 was subsequently administered to the myogenic C2C12 
cell line to test for growth factor bioactivity by measuring ALP activity. Interactions 
between the heparin derivatives and a model positively-charged protein, histone, was 
qualitatively evaluated by differential scanning fluorimetry.   
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Hypothesis III: Longer periods of downhill treadmill running causes tissue damage to 
the insertion region of the supraspinatus tendon in rats, concomitant with an increase in 
cathepsins, a potent class of collagenases and elastases.  
Specific Aim III: Establish an overuse protocol in an inbred strain of rat and evaluate 
changes to tissue organization and expression of active cathepsins.  
 A physiologic model of tendinopathy may provide molecular clues as to what 
causes tissue degradation. An overuse model for the supraspinatus tendon can 
recapitulate the repetitive sliding of the insertion region of the tendon beneath the bony 
acromion. Upon tissue injury, a multitude of proteases may become activated, including 
cysteine cathepsins, which are proteases involved in degradation and remodeling of the 
extracellular matrix, but have been found to be misregulated in diseases such as 
osteoporosis and osteoarthritis [39, 40]. Furthermore, cathepsins may form complexes 
with different types of GAGs and it has been shown that the collagenolytic activity of 
cathepsin K can become inhibited upon binding to heparin, the biomaterial of interest in 
this thesis [41].    
An established decline running protocol was used for an inbred Dahl Salt 
Resistant strain of rat for up to 8 weeks [42]. Tendons were evaluated histologically by 
semi-quantitative histological scoring and circular polarized light microscopy. Gelatin 
zymography was performed at the insertion and midsubstance regions of tendon to 





1.3 Significance and Scientific Contribution 
 The studies in this dissertation provide significant insights into the role of 
naturally-derived, sulfated materials in protein and cell interactions. The established 
growth factor binding ability of heparin was used as an opportunity to develop 
covalently crosslinked heparin-containing hydrogels in order to make coculture systems 
more efficient by sequestering factors around MSCs. The development of a heparin-
containing hydrogel platform for cell encapsulation that can improve pre-treatment of a 
large population of MSCs with a smaller population of differentiated cells is an 
important strategy if the availability of differentiated cells is a limitation. By using 
osteoblasts as a model differentiated cell type, heparin hydrogels were shown to 
influence MSC-mediated expression of osteogenic markers. However, culture with bulk 
heparin-containing hydrogels revealed that geometry and overall heparin content can 
affect the distribution of positively-charged proteins within the hydrogel. This study was 
important in establishing how protein interactions with heparin-containing hydrogels can 
affect protein presentation to encapsulated MSCs and highlights the value of being able 
to tune the amount of heparin and overall sulfation within hydrogels. 
Development of heparin biomaterials without its anti-coagulant feature is 
important for future in vivo work as well as allow us to probe the importance of sulfation 
level and chain conformation in protein interactions. While heparin can act as a cofactor 
in growth factor signaling with FGF-1 and -2 and their receptors, less has been gleaned 
about the interaction of growth factor and heparin complexes that do not affect signaling, 
but still protect growth factors from denaturation. We have shown that even relatively 
small perturbations of sulfation level can drastically affect growth factor protection by 
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heparin. However, with increasing amounts of thermal stress, heparin derivatives with 
intermediate sulfation can maintain BMP-2 bioactivity better than BMP-2 alone, 
indicating that overall sulfation remains a factor in growth factor protection. These 
studies suggest that there is a balance between preserving the protective effects of 
heparin and selective desulfation. As such, these studies on soluble complexes of 
heparin and growth factor can help establish design criteria for sulfated 
glycosaminoglycan-containing hydrogels.  
Adaptation of a tendon overuse model with an inbred strain of rat will allow the 
exploration of cell-based and material-based therapies in the future. The animal model 
and tissue analysis technique used resulted in a fundamental study on a new class of 
enzymes within overused tendon. Cathepsin activity may represent a novel mechanism 
for tissue degeneration upon mechanical overuse of tendon and may be a potential target 
for therapies. Cathepsins can form complexes with heparin, and in the case of cathepsin 
K, the complex may have an inhibitory effect on the protease. This feature will be 
important to explore with heparin-based biomaterials. Overall, this animal model 
provides a framework for studying the gamut of degeneration leading to rupture, and 
provides an opportunity to develop a test bed for targeted growth factor and cellular 
therapeutics to advance understanding of chronic tendinopathy.  
By understanding the progression of tendinopathy in an animal model, 
appropriate heparin-derived cell-based and material-based therapeutics can be developed 
to slow down the progression of disease or supplement current procedures to treat 




BACKGROUND AND LITERATURE REVIEW 
 
2.1 Tendon 
2.1.1 Tendon Function and Structure 
Tendons are fibrous connective tissues that transmit forces from muscle to bone 
to create and stabilize joint movement. Historically characterized as a passive tissue that 
transmits the tensile forces of muscles, tendon has a rather complex role as a stress 
buffer between muscle and bone that can also withstand compression and shear as it 
passes around bony or fibrous structures [43, 44]. Their mechanical utility allows 
muscles to be placed away from the joint and aids in efficient energy expenditure [43, 
45]. Tendons vary in geometry, from ribbons to rounded cords, and can be surrounded 
by differing structures such as synovial sheaths or bursae to reduce friction [46]. 
2.1.1.1 Hierarchical Structure 
The hierarchical structure of tendon extends from the secreted collagen molecule 
to organized tendon tissue. On the smallest scale, 3 polypeptide collagen chains wrap 
themselves into a helix to form water-soluble tropocollagen [2, 47]. Sets of 
tropocollagen molecules self-assemble and crosslink together to form microfibrils, 
which can be further organized into fibers. Collagen fibers are interspersed with 
tenocytes and can appear to have a crimped waveform when the tendon is not loaded in 
tension. Collagen fibers are then organized into tube-like fascicles. Finally, tertiary fiber 
bundles of fascicles and the tendon itself are surrounded by contiguous connective 
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tissues (endotenon and epitenon) that separate subunits and also serve to bring in blood 
vessels and nerves [44, 46].  
2.1.2 Tendon Composition 
Tendon tissues are densely organized tissues composed primarily of collagen, 
proteoglycans and elastin, with collagen comprising up to 70-80% of the dry weight of 
tissue [48]. Of the collagens, ~60% of the dry weight is due to type I collagen, up to 
10% is type III collagen, and type IV, V, and VI are present in smaller amounts [48, 49]. 
The high tensile strength of tendon is primarily due to the parallel arrangement and 
intermolecular crosslinking of type I collagen. Increased type III collagen expression has 
been found in areas of small diameter fibrils, suggesting that it may play a role in tissue 
remodeling [50].   
Elastic fibers, which are responsible for the extensibility of other tissues, make 
up at most 2% of the dry mass of tendon, yet its presence is not uniform across all 
tendons [2]. It has been identified across the entire flexor digitorim profundus tendon 
and is more consistently found near the insertion regions of tendons [51]. Elastic fibers 
are composed of the elastin, fibrillins, and microfibril-associated glycoprotein [52].  
Proteoglycans make up approximately 1-2% of the dry weight of tendon yet may 
aid in withstanding tensile and compressive stresses [2, 53]. Decorin, a small leucine-
rich proteoglycan (SLRP), can bind collagen directly through its core protein or 
glycosaminoglycans (GAGs) to regulate fibrillogenesis and control cell proliferation 
[54-56]. Other SLRPs such as biglycan, fibromodulin, and lumican are present in 
smaller amounts and can also regulate type I collagen organization and fibril diameter 
[56]. Large, or modular proteoglycans, such as aggrecan and versican are negatively-
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charged molecules that can resist compressive forces through their charge-to-charge 
repulsion, and have been found in higher quantities in compressed zones [2, 56, 57].     
The predominate cell type in tendon is the tenocyte, which organize 
longitudinally in-between collagen fibers and extend long cell processes into the 
extracellular matrix (ECM). This specialized fibroblasts is responsible for secreting 
ECM molecules as well as collagen turnover. During development, metabolically active 
tenocytes, tenoblasts, appear rounder, more numerous, and exhibit large endoplasmic 
reticulum-to-cytoplasm ratio, indicative of high protein synthesis. As the tissue matures, 
tenocytes become flatter, fewer in number, and appear to enter a quiescent state [58, 59]. 
Despite being sparsely populated with tenocytes, tendon can still respond to mechanical 
stimuli through the complex network of gap junctions between cells [60]. The 
characterization of resident tendon cells has been to date insufficient, but recent 
identification of tendon stem/progenitor cells may aid the process [61].    
2.1.3 Tendinopathy 
Tendons are highly adaptable, coupling remodeling with increased training load, 
frequency, or duration of loading [62].  However, tendon, for reasons not entirely clear, 
can procure localized damage even while undergoing loadings within physiological 
limits [50]. Since tendons are not very cellularized or vascularized, repair is often 
impaired [47, 63]. Tendinopathy has been adopted as a general term for tendon disorders 
characterized mainly by a combination of pain, swelling, and impaired performance [64, 
65].  
Overuse tendon disorders, or tendinopathies, are increasingly common diagnoses 
for sports and occupational injuries. Tendinopathy can account for approximately 50% 
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of all sports injuries [66]. Musculoskeletal disorders account for 30% of all work-related 
injuries that require time away from work, a measure of severity of injury, with tendon 
disorders requiring a higher median number of days away from work than the average of 
all disorders. Additionally, the highest number of days away from work was highest for 
injuries of the shoulder [67]. Rotator cuff injury is one of the most prevalent orthopaedic 
injuries to the upper extremities, causing pain, weakness, and limited motion of the 
shoulder joint. Once injured, shoulder tendinopathy can become chronic [68]. It has 
been estimated that costs for work-related upper extremity disability carries a direct cost 
of $6.1 billion/year, but this figure is likely higher when indirect costs to employers such 
as loss of productivity, quality, and replacement costs are factored in [69, 70].  
Although the complete etiology of tendinopathy remains to be determined, 
numerous studies have shown that overuse, inappropriate loading, and the internal status 
of surrounding tissues are all factors in tendon disorders [62, 71]. Overuse activity alone 
was demonstrated to cause significant increases in cross-sectional area and decrease in 
maximum stress by four weeks compared to controls in the supraspinatus tendon of rats 
[42, 72].  Histological measures from overuse research show tendons with increased 
cellularity, collagen fiber disorganization, and rounded cell morphology, characteristics 
used to describe tendinopathic tendon [42, 73].  Tendinopathy at the insertion site, the 
enthesis, is one of the most common forms of tendinopathy that affects the supraspinatus, 
common wrist extensor, quadriceps and patellar tendons [74]. The enthesis can exhibit a 
zonal architecture consisting of tendon, uncalcified fibrocartilage, and calcified 
fibrocartilage before insertion into bone [75, 76]. This complex structure may reflect the 
unique loads experienced by the region between tendon and bone [9].   
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2.1.4 Supraspinatus Tendon  
2.1.4.1 Anatomy 
The glenohumeral joint consists of the humeral head positioned within the 
glenoid fossa of the scapula and stabilized by the rotator cuff capsule. The rotator cuff 
capsule contains ligaments and tendons, which include the supraspinatus, infraspinatus, 
teres minor, and subscapularis tendons, which work antagonistically to stabilize 
movement [77]. On the anterior side, the subscapularis inserts onto the humeral neck 
and lesser tuberosity. The supraspinatus attaches to the superior face of the greater 
tuberosity, followed by insertion of the infraspinatus on the posterior side. Finally, the 
teres minor tendon inserts to the greater tuberosity, inferior to the infraspinatus tendon. 
These tendons interdigitate with their neighboring tendons, leading to the possibility of 
load sharing [77].   
The supraspinatus muscle works in concert with the deltoid muscle to allow arm 
abduction, which causes the supraspinatus tendon to pass under the coracoacromial arch, 
which consists of the coracoacromial ligament spanning between the bony acromion and 
coracoid process [78]. The geometry of the supraspinatus tendon differs across the 
tendon. The anterior portion of the supraspinatus tendon, which is characterized by a 
cord-like appearance, is approximately twice as long as the posterior region, which is 
wider and flatter [79, 80]. The insertion (lateral) region where tendon inserts into bone 
shows a zonal transition from tendon tissue to fibrocartilage tissue and is commonly 
termed the “critical zone” for the preponderance of tears that occur in that region [81].  
2.1.4.2 Factors in Supraspinatus Tendinopathy 
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In addition to acute injuries, chronic degeneration of tissue can cause tears within 
the supraspinatus tendon. While there is no consensus as to which factors ultimately 
cause tendon degeneration, it is likely a combination of causes that make tendons 
susceptible to injury. Overuse of the rotator cuff is commonly accepted as one factor for 
injury, with many athletes who require overhead actions exhibiting chronic tendinopathy 
[82, 83]. Other causative factors have been grouped into intrinsic and extrinsic factors. 
Intrinsic factors include any changes within the tendon tissue that may alter the state of 
the tissue. This may include changes to vascularity within the tissue and to the 
compositional state of the ECM [84]. These factors may relate to the overall status of the 
patient such as age, activity level, and overall health. It has been shown that while 
collagen content in healthy supraspinatus tendon does not change with age, collagen 
remodeling may naturally increase after a certain age, possibly as a secondary response 
to a change within the tendon [85].  
The extrinsic factors to tendon degeneration are based on structures outside the 
tendon that may cause damage to the tissue, primarily through impingement. 
Impingement can be caused by the coracoacromial arch, which lies superior of the 
supraspinatus tendon. Certain geometries of the acromion were correlated with higher 
incidences of tendon tears [86-88]. When the anterior portion of the acromion was more 
hooked, rather than flat, the supraspinatus tendon was more likely to become 
compressed, resulting in primary impingement. Impingement by a lateral extension of 
the acromion, by the coracoacromial ligament, or by the posterosuperior glenoid labrum 
has also been suggested as causative factors [89-91]. Secondary impingement can occur 
when preceded by an event that produces joint instability. Commonly seen in athletes, 
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imbalance in trained muscles can cause increased humeral head translation outside the 
glenoid fossa, leading to tendon impingement [92, 93].   
2.1.4.3 Location of Supraspinatus Tendon Tears 
While most tears have been observed to occur at the insertion region, there is less 
agreement on whether more tears occur in the anterior versus posterior region [80, 94]. 
More conclusive data has shown that the articular side of the tendon can experience 
greater forces when the abduction angle is ~60%, as this side may undergo compression 
from the humeral head [81, 95]. However, with higher angles of abduction, the bursal 
side may experience greater strain [95]. This mismatch in strain between the articular 
and bursal faces of tendon may cause intratendinous shear and lead to microtears, 
particularly on the articular surface [81]. While tears are a clear result of overuse, 
biochemical changes within the tissue prior to any tears can be informative on the 
pathophysiology of tendionopathy.  
2.1.4.4 Tissue-level Changes in Tendinopathy 
Histopathological characteristics of tendinopathy can vary widely, but it is 
accepted that overuse tendinopathy can proceed without an observable inflammatory 
response [96]. Instead, collagen fiber separation and disorganization, increase in non-
collagenous extracellular matrix, and increase number of cells are observed in overuse 
tendinopathy [96-98]. The pathogenesis of tendinopathy has been explored by 
elucidating cellular responses to mechanical loads. In a study of the supraspinatus 
tendon that underwent compression, transcription profiling revealed increased 
expression of cartilage-associated genes such as procollagen type 2 alpha1 (Col2a1), 
aggrecan (Agc1), and sex determining region Y-box 9 (Sox9) [99]. Increase in decorin, 
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versican and aggregan gene expression was followed by an increase in total sulfated 
GAG content after rotator cuff overuse in a rat [100]. These findings suggest that the 
overused tendon shifted toward a cartilaginous phenotype, possibly as a result of the 
tendon repeatedly passing through the acromial arch. The exact mediators that cause 
collagen disorganization have not been fully defined in supraspinatus tendon overuse, 
but change in cell status and release of messenger molecules have been purported to 
contribute to tendon degeneration. Stress-activated programmed cell death may cause a 
loss of tissue maintenance and release of nitric oxide, a molecule that can modulate 
matrix metalloproteinases have been described after tendon overuse [101, 102].  
2.1.4.5 Treatment Limitations  
After tendon injury, tendon may not recover its original mechanical strength and 
may predispose the remaining tendon to injury [63, 79]. Conservative treatments may 
not address the functional recovery of the supraspinatus tendon, and in cases of tendon 
rupture, surgery may be needed to reattach the tendon. When possible, the tendon is 
reattached to the greater tuberosity through anchoring and suturing [103]. While treating 
recalcitrant pain and tendon tears, reinjury rates have been as high as 57% and do not 
address the underlying pathophysiology that can lead to tendon ruptures and re-tears [4]. 
Even as commercial ECM materials become available for rotator cuff repair with the 
hopes of stimulating intrinsic healing potential, a clearer understanding of how overuse 





2.2 Review of Current Work in Understanding Tendon Injury 
 Different animal models and tendon injury mechanisms exist, and the results 
inform different aspects of tendon injury. An acute tear, commonly performed by tendon 
transection, recruits an inflammatory response and has been useful in identifying cell 
types and biomolecules that participate in tendon healing. These studies may inform the 
types of signaling that should be recapitulated in studying regenerative strategies for 
tendon-to-bone repair [105]. On the other hand, mechanical overuse models, if they 
resemble the anatomy and function of human tendons, can be better models for 
elucidating mechanisms in chronic tendon injuries that are clinically relevant.    
2.2.1 Intrinsic Growth Factor Response to Acute Tendon Injury 
The intrinsic healing capacity of tendons has been studied in order to develop 
regenerative treatment options. When tendon was transected and allowed to heal, an 
upregulation of growth factors from different cell types were identified. In a healing 
rabbit rotator cuff, fibroblast-secreted FGF-2 was active through the proliferation and 
remodeling stages and may stimulate the proliferation of resident tendon cells [106, 107]. 
Platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), transforming 
growth factor-β (TGF-β), and bone morphogenetic protein (BMP)-12 were similarly 
found during tendon healing [106, 108]. These factors can have overlapping roles in cell 
proliferation, matrix synthesis, and chemotaxis of cells. Thus these growth factors have 
been used to accelerate and improve tendon healing. Direct injection of FGF-2 was 
shown to increase cell proliferation and expression of type III collagen 7 days after 
injection into a rat patellar tendon [109]. PDGF, a potent mitogen that is stored in α 
granules and secreted by a variety of cells, was able to stimulate collagen and non-
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collagen protein synthesis in tendon explants and improved the mechanical properties of 
healing tissue [110, 111].  
2.2.2 Chronic Tendon Injury Model 
 Chronic tendon injuries in animals can be induced through overuse exercises and 
have been informative in describing modes of tendon injury that consider anatomical 
and functional relevance to human tendon injuries. The rat was selected as an 
appropriate model to replicate shoulder overuse due to similar soft tissue and bony 
anatomy around the supraspinatus tendon [112]. With overhead movement caused by 
downhill running, the supraspinatus tendon shows an excursion beneath the acromion 
similar to human supraspinatus tendon [105]. This animal model has shown evidence of 
pro-inflammatory markers such as elevation of cyclooxygenase-2 and five-lipoxygenase 
activating protein gene expression [113]. However, inflammatory cells are not typically 
seen in this overuse model, indicating that inflammatory mediators may be induced in 
the tissue by other cytokines [42, 113]. Overuse may also cause early expression of IGF-
1 and increased expression of nitric oxide synthase, but their roles in tendinopathy have 
not been determined [102, 114]. The tendon changes in this overuse model has been 
shown to be repeatable, with increases in cartilaginous features, most likely due to 
repetitive compression as the supraspinatus tendon slides beneath the acromion [99, 115].   
 
2.3 Proteolytic Degradation of Collagen 
2.3.1 Matrix Metalloproteinases 
 Human matrix metalloproteinases are a family of at 23 zinc-dependent 
endopeptidases, capable of cleaving a host of extracellular proteins. Most MMPs display 
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a similar overall structure consisting of a propeptide region, a zinc-containing catalytic 
domain, a linker peptide, and a hemopexin domain [116]. The MMP family can be 
categorized by their typical substrates: 1) collagenases (MMP-1, MMP-8, MMP-13), 2) 
gelatinases (MMP-2, MMP-9), 3) stromelysins (MMP-3, MMP-10), 4) matrilysins, and 
5) membrane type MMPs [117]. While baseline MMP activity is low, they can be 
readily induced by inflammatory cytokines, growth factors, cell-cell, and cell-matrix 
interactions [118]. They are secreted as latent enzymes and can be activated by other 
enzymes at physiological pH [119]. The collagenases are able to degrade interstitial 
collagens of type I, II, and III into characteristic ¾ and ¼ fragments, by unwinding the 
collagen helix and cleaving α chains in succession [120]. Gelatinases can degrade the 
smaller collagen fragments released during activity of the collagenases, as well as 
directly cleaving collagen types IV, V, and XI. While MMP-2 is a gelatinase, it can also 
directly cleave type I, II, and III collagen, although it is much less active than MMP-1 
[121]. The stromelysin MMP-3 is known to play an important function in activating pro-
MMPs and can be crucial in initiation collagen degradation [122]. MMP activity is 
tightly monitored by reversibly binding 1:1 to tissue inhibitors of metalloproteinases 
(TIMPs).   
 Due to the importance of MMPs in tissue maintenance and remodeling, as well 
as their presence in various diseases, they have also been studied in degenerative tendon. 
Macroscopically normal supraspinatus tendons have demonstrated relatively high levels 
of MMP-1, MMP-2, and MMP-3, suggesting that this tendon undergoes high turnover 
and remodeling compared to the biceps brachii tendon, which rarely experiences 
pathology [123]. However, ruptured supraspinatus tendons showed increased activity of 
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MMP-1 and decreased activity of MMP-2 and -3, resulting in significant amounts of 
denatured collagen and less overall collagen that may weaken the overall mechanical 
properties of the tendon [123, 124]. Decreased expression of MMP-3 has been correlated 
to increased expression of proteoglycans in chronic tendinopathy, suggesting that 
decreases in certain MMPs may also prove to be a pathological feature [125]. 
Additionally, an imbalance between MMPs and TIMPs, which has been shown with torn 
rotator cuff tendons, may signal a disruption in tissue homeostasis [126].  
2.3.2 Cysteine Cathepsins 
 Cysteine cathepsins are mostly monomeric papain-related proteinases with 
currently 11 members. These proteinases have a wide range of functions, from bone 
remodeling to wound healing to antigen processing [127-129].  They are optimally 
active at acidic pH and are usually located within lysosomal compartments [130]. 
Cathepsins generally share the same overall structure of two domains separated by a 
“V”-shaped catalytic region. On one side of the catalytic domain, α helices dominate, 
while on the other side, a β barrel motif exists [131]. In the catalytic region, a conserved 
cysteine residue on one side coordinates with a histidine residue on the opposite side at 
the β barrel region to cleave a substrate [132]. Cathepsins are translated with a 
propeptide region that can be enzymatically cleaved by other proteases such as cathepsin 
D or pepsin, or removed autocatalytically at acidic pH [132, 133]. Since high 
concentrations of cathepsins can exist within lysosomes, they are tightly regulated by a 
reversible, tight-binding superfamily of inhibitors. The cystatin superfamily of cathepsin 
inhibitors consists of 3 families: 1) stefins, 2) cystatins, and 3) kininogens [134]. Stefins 
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lack a signal peptide and primarily act intracellularly, while cystatins and the larger 
kininogens can act extracellularly [132]. 
 Cathepsin L is potent in degrading elastin and collagen type I, more efficiently 
than cathepsin B [135, 136]. Cathepsin L can cleave collagen at the telopeptide regions, 
causing loss of crosslinks and instigating depolymerization. Cathepsin K was originally 
detected in osteoclasts and ovaries, but its expression has subsequently been detected in 
epithelia and other cells [137]. Cathepsin K is able to cleave collagen I and II through 
the triple helix near the N-terminal region, rather than the well-defined collagenase-
sensitive site, as well as the telopeptide regions [138]. This is in contrast to collagenases 
which can typically only cleave at one or the other [139].  
  
2.4 Cocultures of MSCs with Differentiated Cell Types11 
Paracrine and autocrine signaling can affect gene expression, protein production, 
proliferation, and apoptosis in the tissue microenvironment – significant issues in 
forming physiologically viable tissues, from development to remodeling to regeneration 
[35]. The concept of cocultures, studies involving at least two different cell types to 
understand the potential cellular crosstalk effects, attempt to address the paradigm of 
tissues as modular systems that cannot be treated in isolation. With this perspective, 
crosstalk between cells affects the metabolism and fate of neighboring cells. Coculture 
systems have the potential to expand the available number of cells for clinical 
applications by using signals from a small pool of primary cells to induce differentiation 
in a large population of stem cells [36]. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Portions of this section were adapted from Seto SP, Temenoff JS. Coculture Systems for Mesenchymal 
Stem Cells. In: Fisher JP, Mikos AG, Bronzino JD, Peterson DR, eds. Tissue Engineering: Principle and 
Practices. Boca Raton, FL: CRC Press; 2012:21.1-21.6. 
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2.4.1 MSC Cocultures with Chondrocytes 
Recent results with chondrocytes cultured in 3D environments have shown that 
cocultured MSCs express osteogenic phenotypes. Articular chondrocytes encapsulated 
in alginate beads and suspended over a monolayer of bone marrow-derived MSCs (BM-
MSCs) remained viable in the system for up to 21 days. Alkaline phosphatase (ALP) 
expression, an indicator of mineralization, was elevated in MSCs with exposure to 
chondrocytes. In fact, the longer the time in coculture, the more accelerated the calcium 
deposition and phenotypic change from spindle-shaped to osteoblast-like cuboidal-
shaped [140]. An osseous phenotype could form by day 28 when both MSCs and 
articular chondrocytes were encapsulated in alginate and cultured in the presence of 
dexamethasone and ascorbic acid, suggesting that one of the cell types was maturing or 
differentiating [141]. By utilizing cells from two different species of animals to allow 
specific gene probing, the cartilaginous phenotype of the coculture was shown to 
originate from the chondrocytes, but higher glycosaminoglycan (GAG) production and 
type II collagen production was seen with a greater number of MSCs in the coculture 
system [141]. Several additional studies have utilized encapsulated MSCs cocultured 
with chondrocytes cultured in 3D, and have shown increased expression of chondrocyte 
markers such as type II collagen and aggrecan, but did not report the presence of 
hypertrophic markers [142-144].  
MSCs are presumed to be more sensitive to contact-dependent signals than more 
differentiated cells, which may make them amenable to direct coculture [145]. ALP 
activity was measured in cocultures that varied the relative number of cells to 1:1 and 
1:2 MSC to chondrocyte pellet co-cultures. Both groups suppressed ALP activity, but 
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the 1:2 group exhibited a significantly lower ALP activity than controls [146]. 
Furthermore, these MSC-chondrocyte cell pellets fully inhibited mineralization when 
implanted subcutaneously into immunodeficient mice, suggesting that certain cocultures 
can inhibit chondrocyte hypertrophy [146]. Conversely, the MSC-only pellet produced a 
calcified cartilaginous tissue when implanted and exhibited the presence of collagen 
type X and elevated ALP levels. When rabbit MSCs were cultured with chondrocytes in 
hydrogels at ratios of 1:1 and 3:1, higher type II collagen and aggrecan expression was 
observed for the 1:1 group compared to the 3:1 group [144]. Taken together, the relative 
amount of chondrocytes in the co-culture system may affect the levels of chondrogenic 
expression observed as well as the degree of chondrocyte hypertrophy. Stem cell contact 
with articular chondrocytes in a 3D environment may help prevent hypertrophy [147].   
2.4.2 MSC Cocultures with Osteoblasts 
Studies with conditioned media from osteoblasts have indicated that osteogenic 
genes and phenotype can be induced in stem cells, but some of these studies utilized 
dexamethasone, a potent glucocorticoid, which can mask signaling between cells [148, 
149]. Results from these conditioned media experiments contradict another study in 
which mature osteoblasts were only slightly osteogenic toward C3H10T1/2 stem cells, 
indicating that media type can affect the phenotype observed [150]. Furthermore, the use 
of conditioned media is not representative of the dynamic signaling that can occur 
between two cell types over time.  
Two-way signaling between osteoblasts and MSCs may produce a differentiation 
niche similar to that seen in the natural microenvironment [151]. Murine osteoblasts 
cocultured with MSCs in a transwell system showed no change in proliferation or gene 
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expression over 3 weeks in dexamethasone-free medium. The cocultured MSCs, 
however, showed increased expression of runx2, osterix, osteopontin, and bone 
sialoprotein at 3 weeks compared to MSC-only controls [152].   Similarly, human MSCs 
cocultured with human osteoblasts exhibited upregulation in bone sialoprotein-2, 
lipoprotein receptor, ALP, and osteocalcin by day 14 when cocultured with twice the 
amount of osteoblasts than MSCs [151]. The results indicate that soluble factors from 
osteoblasts can induce MSCs into a more osteogenic phenotype by upregulating both 
early and late bone markers over time.  
Cell-to-cell contact between MSCs and osteoblasts can enhance communication 
between cells. Gap junctions, transmembrane channels between neighboring cells that 
allow communication through the cytoplasm, are present between osteoblasts, 
osteoclasts, and osteocytes [153]. Connexin 43 is the most abundant gap junction in 
bone and beyond allowing cells to respond to external stimuli, has been shown to be 
required for osteoblast differentiation and function [153-155]. Human osteoblasts were 
shown to couple to bone marrow stromal cells and allow Luciferase dye transfer, a 
phenomenon that was inhibited by the application of octanol, an inhibitor of gap 
junction communication [156].  
The exact mechanisms that link cell contact or soluble signaling to gene 
expression remain elusive, but depend on the types of signals, downstream effects, and 
cell contact proteins involved. The Wnt pathway was identified to play an inductive role 
in MSC differentiation in studies comparing indirect and direct co-culture without 
osteogenic factors [152, 157]. The increased secretion of Wnt by osteoblasts was 
observed with a concomitant increase in β-catenin and TCF/LEF1 levels, downstream 
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effectors of Wnt, in MSCs cultured indirectly with osteoblasts. However, the 
upregulation of bone-related markers in indirect co-culture were reversed when 
osteoblasts were cultured in direct contact with MSCs in a ratio 1:4 in a mixed 
monolayer [152]. Direct cell culture offset the stimulatory effect of osteoblasts by 
crosstalk between cadherin-β-catenin pathway and the Wnt pathway. In this study, it is 
suggested that soluble factors can induce osteogenesis in MSCs while cell contact can 
reduce osteogenic differentiation potential.  
 
2.5 Bone Morphogenetic Protein-2 (BMP-2) 
2.5.1 In Vivo Roles of BMP-2  
BMPs are part of the transforming growth factor-β superfamily and play vital 
roles in skeletal development [158]. Bone morphogenetic proteins (BMPs) were first 
identified as a component of decellularized and demineralized bone matrix that had 
bone-forming capabilities [159, 160]. They were subsequently shown to be sufficient in 
inducing cartilage and heterotopic bone in vitro and in vivo [24, 161, 162]. BMP-2, -4, 
and -7 are disulfide-linked dimers that have been found to have many roles in bone and 
cartilage development as well as postnatal fracture healing [163]. In developing limbs, 
BMP-2 is expressed in the mesenchyme surrounding early cartilage condensation and 
may play roles in cell recruitment and differentiation of cells into chondrocytes [164]. 
Additionally, BMP-2 can accelerate the transition of proliferating chondrocytes to 
hypertrophy [165]. In the early stage of endochondral ossification in bone fracture 
healing, many cells increase expression of BMPs in the callus, suggesting that BMPs 
participate in differentiating cells in the callus [165]. Specifically, they have been shown 
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to be a potent factor in mesenchymal stem cell differentiation into osteochondrogenic or 
osteoblastic precursor cells [21, 23, 24].  
2.5.2 BMP-2 Structure 
Bone morphogenetic protein-2 (BMP-2) is structurally very similar to BMP-4. 
BMP-2 exists as a homodimer with each subunit of approximately 114 residues 
stabilized by 3 intrachain disulfide bonds that form a cysteine knot [160, 166]. The 
overall structure of each subunit is composed of predominately β-sheets in addition to 4 
α-helices [166, 167]. While the monomer differs from many other globular proteins 
because it lacks a substantial hydrophobic core, 2 hydrophobic cores are formed upon 
dimer formation between the α3 of one subunit and the β-strands of the other subunit, 
forming a single disulfide bond. While it has been observed that BMP-2 appears to be 
relatively stable since it is retrieved by harsh chemical treatments [160], the solubility of 
the non-glycosylated form is unusual because it prefers an acidic environment and its 
solvent-accessible hydrophobic residues tend to make BMP-2 aggregate [168]. 
2.5.3 Signaling Pathway 
BMPs can signal through binding serine/threonine kinase receptors, composed of 
type I and II subtypes [169]. After heterotetrameric clustering of these receptors, signal 
transduction proceeds through Smad 1/5/8, whereby the phosphorylated Smad molecule 
associates with Smad 4 and ultimately translocates to the nucleus to activate 
transcription factors such as Runx2 [170]. BMP in the extracellular space can be 
inhibited by noggin or chordin by directly interfering with the receptor binding epitope 
[171].   
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2.5.4 Clinical Use of BMP-2 
The current approved delivery system for BMP-2 is via an absorbable collagen 
sponge and has been used in spinal fusion as the Medtronic Infuse® Bone Graft. This 
product, introduced in 2002, has been approved for spinal fusion, open tibial fractures, 
and sinus augmentation [172, 173]. However, BMP-2 has low affinity to collagen and 
has been shown to have a short half-life in solution [28, 174]. Possibly to counter this, 
delivery vehicles are often loaded with supraphysiological doses of BMP-2 [29], which 
increases overall costs and has been shown to have adverse effects, such as bone 
resorption [27, 29, 172, 175].  
2.5.5 BMPs in Tendon-to-Bone Integration 
BMP-2 and BMP-7 have been detected during patellar tendon healing, 
suggesting that these molecules take part in intrinsic healing [176]. Resident tendon 
stem/progenitor cell populations, although just a small fraction of tendon cells, can be 
induced to form osteotendinous junctions with treated with BMP-2 [61]. When BMP-2 
was used to calcify tendon prior to fixation in a bone tunnel, better integration and 
higher ultimate failure loads were observed [17]. BMP-2, in a low dose, may accelerate 
the healing response between tendon and bone causing the tendon to fail away from the 
repair site by as early as 4 weeks [18].  
2.5.6 Heparin-Binding Region of BMP-2 
When the N-terminal of BMP-2 was proteolytically cleaved, some unspecific 
binding and variability in biological activity was reduced, indicating that this region may 
take part in diverse binding, dependent on cell type and environment [169]. It has been 
since shown that this sequence preceding the first cysteine knot at the N-terminal is 
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heparin binding [168]. Unlike some other TGF-β factors, this region is not covalently 
attached to the protein core by disulfide bonds [177], making this region relatively 
flexible. The crystal structure determination of BMP-2 has often characterized this 
region as a disordered area with primarily basic residues [168, 177]. This disorder has 
been implied to be advantageous in binding the heterogeneous structures of 




2.6.1 Structure and Biosynthesis 
Heparin is a linear, helical glycosaminoglycan (GAG) polymer composed of 
repeating units of uronic acid and glucosamine residues [30, 179]. It has the highest 
negative charge density of known biomolecules due to numerous carboxyl and sulfate 
groups. Heterogeneous in weight, heparin ranges from 3-30kDa (average 15kDa) [180]. 
A disaccharide unit on average contains 2.7 sulfate groups, often substituted on the 6O- 
and N- position on glucosamine; and the 2O- position on iduronic acid [30, 181]. The 
uronic acid residues are primarily composed of L-iduronic acid and exhibit 
conformational flexibility that may aid in specific protein interactions [182, 183]. 
Furthermore, the N- position on glucosamine can be left unsubstituted, acetylated, or 
sulfated, thereby increasing heterogeneity in sulfation [184].   
Heparin, and the structurally similar heparan sulfate proteoglycan, has many 
functions that include regulating cell adhesion and protease storage [185, 186]. 
Biosynthesis of heparin and heparan sulfate begin similarly with non-sulfated GAG 
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molecules attached to a protein core. In post-processing steps, sulfotransferases couple 
sulfates to the pyranose subunits and a sequence of proteases ultimately release heparin 
from peptides [187, 188]. Unlike heparan sulfate, which can be found widely distributed 
on cell surfaces, heparin is primarily found in mast cells and some hematopoietic cells 
[189]. 
2.6.2 Heparin-Protein Interactions   
2.6.2.1 Antithrombin III 
Heparin can have very specific interactions with proteins, such as that described 
with the glycoprotein antithrombin III. Antithrombin III was found to bind with heparin 
at high affinity at a 1:1 stoichiometry and accelerate its inhibition of thrombin and factor 
Xa [190]. It was found that a very specific sequence of heparin, a pentasaccharide 
sequence with a relatively rare 3-O sulfate on glucosamine, was the smallest and most 
necessary fragment for activity [191-194]. This sequence also required a conformational 
change of iduronic acid into a skew boat form, further supporting that a change in 
geometry of heparin was needed to induce a corresponding change in antithrombin [193].  
2.6.2.2 Fibroblast Growth Factors 
The most researched protein-heparin interactions after antithrombin-heparin are 
likely those with fibroblast growth factor (FGF)-1 and -2. Although they have 
similarities, FGF-1 exhibits lower affinity for heparan sulfate than FGF-2 [195]. 
Heparin-binding amino acid sequences have been identified for these growth factors and 
it has been determined that variations in heparin sulfation can affect binding and 
signaling [196-198]. Only the N- and 2-O sulfation of heparin was necessary to bind 
FGF-2, but stimulation of FGFR1 required the presence of 6-O sulfation on heparin 
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[199]. In contrast, 6-O sulfation was necessary for the biological activity of FGF-1 [200, 
201]. While FGF-1 and FGF-2 are structurally similar, their interaction with heparin 
differs. Heparin behaves more as a co-factor for FGF-2 signaling, in which it helps 
dimerize FGF-2:FGFR1 units [31]. In the case of FGF-1, multiple FGF-1 molecules 
complex with heparin in solution and subsequently bind to receptors that are induced to 
dimerize [202]. In both cases, while there may be some controversy on to the minimal 
binding sequence, heparin is necessary in promoting FGF signaling when surface 
heparan sulfates are absent [31, 203, 204].  
Binding to heparin can protect FGF-1 and -2 from denaturation due to heat and 
proteolysis, likely by forming specific interactions that prevent protein unfolding or 
access to proteases [205-207]. It was shown that a 5-molar excess of heparin could 
protect FGF-1 from 1% trifluoroacetic acid treatment or heat treatment at 65°C for 5 
minutes, while only an almost stoichiometric 1:1 amount of heparin was needed to 
protect FGF-2 from the same treatments [205]. Furthermore, heparin was able to protect 
FGF-2 from 2% trypsin cleavage for up to 8 hours, while FGF-2 without heparin was 
degraded by 3 hours [208].     
There are other heparin-binding proteins such as BMP-2 and heparin-binding 
epidermal growth factor-like factor with identified heparin-binding domains [168, 209]. 
Both these growth factors contain heparin-binding domains near the N-terminal, but 
neither growth factors require heparin for growth factor-induced signaling such as in the 
case with FGF-1 and -2. Rather, exogenous heparin can maintain BMP-2 concentrations 
in cell culture medium by preventing BMP-2 inhibition by noggin [174]. While 
endogenous cell-surface heparan sulfate molecules sequester BMP-2 and mediate BMP-
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2 internalization, heparin may play a role in keeping BMP-2 away from the cell surface 
and limiting BMP-2 endocytosis [22, 210].  
2.6.3 Heparin and Heparan Sulfate Mediation of Stem Cell Differentiation 
2.6.3.1 Changes in expression of heparan sulfate during stem cell differentiation 
Heparan sulfate has a critical role in binding and activating growth factors for cell 
signaling in tissue development. More recently, there has been evidence of the evolving 
presence and structure of proteoglycans themselves in stem cell biology. Murine 
embryonic stem cells exhibited enhanced heparan sulfate (HS) synthesis following a 
transition into embryoid bodies or endodermal cells [211]. Also, HS shifted from an 
unusually low sulfated variant in embryonic stem cells to a more highly sulfated form in 
progenitor cells [211, 212]. This change was accompanied by the relatively early activity 
of N-sulfotransferases, followed by 6O, 3O-sulfotransferases [212]. This research 
suggests that the presence of certain proteoglycans such as HS may signal cell exit from 
a pluripotency state to a more differentiated cell type.  
2.6.3.2 HS and Heparin in osteogenic differentiation 
Exogenous addition of HS has been shown to increase the expression of 
osteoblast markers in osteogenic environments. Local administration of bone derived HS 
to a rat femoral fracture caused an increase in callus size alongside increased expression 
of Runx2, ALP and FGF-1, suggesting that HS could enhance osteogenesis in 
endogenous cells [213]. When HS proteoglycans from differentiated osteoblasts were 
administered to pre-confluent, preosteoblast MC3T3-E1 cells, Runx2, ALP, and 
osteopontin expression was enhanced [214]. Additionally, the source of HS had an effect 
on cultures, as soluble and surface-derived HS upregulated different FGF receptors, 
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likely in response to the different core proteins from the different sources. Endogenous 
liberation of HS by heparinase treatment can also cause an increase in osteogenic gene 
expression, in addition to an increase in BMP signaling through the Smad pathway [215]. 
This suggests that HS may enhance the changes in growth factor presentation that can 
cause shifts in cell membrane receptors [216, 217].   
While heparin lacks the core protein of HS, the presence of heparin has been 
shown to enhance osteogenic differentiation of MSCs without the addition of growth 
factors as well [218]. In contrast to the above results, some studies have shown that 
heparin can inhibit osteoblastic differentiation or decrease the number of bone nodules 
formed, but these studies were conducted with soluble heparin in which medium was 
replenished regularly [219, 220]. Frequent replenishment may deplete the concentration 
of growth factors that remain bioactive while bound to heparin in solution.  
 
2.7 Heparin-Containing Delivery Systems 
2.7.1 Physical Incorporation of Heparin 
Heparin can be incorporated into delivery systems in a variety of methods. One 
avenue is to use heparin in its native form without chemical modification. This has the 
benefit of retaining biological activity of heparin, which was shown to decrease with 
higher degrees of chemical modification [34]. Polyelectrolyte multilayer coatings are 
produced by layer-by-layer deposition of alternating cationic and anionic 
polyelectrolytes. By adjusting fabrication techniques, layer thicknesses and capacity for 
growth factor storage can be tuned [221, 222]. Heparin layered with cationic chitosan on 
tissue culture polystyrene had to ability to store and delivery FGF-2 to induce cell 
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proliferation better than soluble delivery of FGF-2 [223]. The ability for heparin to 
interact with growth factors and retain its bioactivity motivates the use of heparin. With 
this concept, complexes between heparin and positively-charged proteins directly can be 
formed. When the complex is strongly hydrated, a soluble complex can form, and with 
decreasing amounts of hydration where the net charge approaches 0, a coacervate can 
form as a liquid-liquid phase transition [224].  A coacervate of heparin, FGF-2, and a 
polycation to neutralize remaining charges had the properties of remaining injectable, 
reducing burst release, and preserving FGF-2 bioactivity [225, 226]. The complexity of 
the unmodified heparin delivery system can increase as more features are required. To 
combine an enzymatically degradable hydrogel with affinity features, a fibrin-based 
delivery system was developed with covalent attachment of a heparin-binding peptide 
that electrostatically immobilized heparin [227]. When this system was used to deliver 
TGF-β in a tendon defect, accelerated healing at early timepoints was observed, with 
improved tendon properties by 28 days [228].  
2.7.2 Covalent Crosslinking of Heparin into Hydrogels   
Chemical modification of heparin to allow covalent attachment to delivery 
systems, particularly hydrogels, has been investigated for protein delivery and cell 
encapsulation where release of soluble heparin is not desired. Covalent crosslinking of 
polymers can occur with radical initiation or Michael-type additions between 
constituents with reactive side groups [229, 230]. Heparin, with its numerous carboxyl 
and hydroxyl groups, is amenable to chemical substitutions such as thiols, methacrylates 
and malemides [231-233]. Since side groups such as carboxyls can be important in 
growth factor binding, a balance needs to be achieved where enough chemical 
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modification allows robust hydrogel formation while also retaining bioactivity [231, 
234]. It has been shown that increasing the amount of methacrylation from 6% to 22% 
on heparin can significantly reduce the amount of BMP-2 binding, although the level of 
affinity needed may depend on the application [34]. The addition of small quantities (up 
to 1% w/w) of heparin into a delivery system was shown to attenuate burst release and 
prolong the time of growth factor release [233]. By introduction of cell-adhesive 
peptides such as RGD, cell encapsulation was also achieved within heparin-containing 


















DIFFERENTIATION OF MESENCHYMAL STEM CELLS IN HEPARIN-
CONTAINING HYDROGELS VIA COCULTURE WITH OSTEOBLASTS2 
 
3.1 Introduction 
Tissue engineering approaches, using combinations of cells, scaffolds, and 
bioactive factors, have been explored for the restoration of orthopaedic tissues such as 
bone, ligaments, and cartilage [236-238]. An attractive cell source for cell therapies is 
mesenchymal stem cells (MSCs), multipotent cells with significant proliferative and 
regenerative capacity in vitro [239]. In addition to their expansion potential, MSCs have 
been differentiated toward osteogenic, chondrogenic and myogenic lineages, enabling 
their use in reconstructing orthopaedic tissues [240]. Direct delivery of MSCs into tissue 
defects has shown some salutary effects [241], but the in vivo therapeutic efficacy can be 
improved by priming MSCs toward the desired cell lineages prior to implantation [242]. 
In prior work, pre-treatment of MSCs in differentiation media for as little as 4 days 
showed enhanced MSC-mediated chondrogenic and osteogenic extracellular matrix 
production when implanted in vivo [243, 244]. While treatment with specified media 
formulations has shown to be effective in “pre-differentiating” cells prior to 
transplantation in some cases, recapitulating the native differentiation environment 
where multiple morphogens are presented temporally to MSCs remains desirable, 
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especially for cells with less characterized differentiation pathways such as 
intervertebral disc cells [245]. 
Coculture systems have been utilized previously to enhance proliferation of cells 
of interest and differentiate stem cells with a population of differentiated cells [32, 246]. 
Certain cell types, such as intervertebral disc-derived cells, as well as osteoblasts, have 
limited expansion capabilities ex vivo [36, 243] so the ability to regulate a large 
population by culturing with a small pool of primary cells would be useful in a variety of 
cell-based therapies. In this study, we have chosen to examine osteogenic differentiation 
of human MSCs cocultured with human osteoblasts as a proof-of-concept experiment, 
but the approach described could be easily transferred to other cell types of interest for 
specific applications.  
Heparin, a highly-sulfated linear glycosaminoglycan (GAG), (and the 
structurally similar heparan sulfate) has been implicated in many biological processes 
such as tissue morphogenesis, wound repair, establishment of morphogen gradients, and 
regulating the availability of growth factors to cells [217, 247]. In addition, there is 
evidence that complexation with heparin protects growth factors from enzymatic 
degradation and may catalyze growth factor presentation to cells, inducing such 
responses as proliferation and MSC differentiation [247-250]. These functions have 
prompted investigations of the use of heparin as a drug delivery system and cell carrier. 
Heparin has been immobilized in different scaffolds including poly(ethylene glycol)-
based materials [235, 251, 252]. Recently, heparin has also been integrated in cell-
adhesive and enzyme-sensitive hydrogels to enable cell-mediated degradation of 
heparin-containing carrier materials [253, 254]. The presence of heparin was 
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demonstrated to attenuate burst release of bone morphogenetic protein-2 (BMP-2) and 
basic fibroblast growth factor, both signals associated with osteogenesis [251, 255], 
from PEG-based hydrogels.  
While much previous work with heparin-based biomaterials has focused on their 
use as a growth factor release vehicle and/or suitability for cell encapsulation, few 
studies have been conducted investigating heparin-containing biomaterials’ role in 
sequestration of multiple soluble factors from the culture environment. In response, we 
have designed synthetic, poly(ethylene glycol)-based hydrogels with varying degrees of 
incorporated heparin to examine if the amount of heparin present influences osteogenic 
differentiation of embedded MSCs when cocultured with osteoblasts. For many 
orthopaedic applications, hydrogels are advantageous as they provide a 3D culture 
environment that is more representative of native tissues while providing a high degree 
of control over the properties surrounding encapsulated cells [256]. In these experiments, 
MSCs were encapsulated in hydrogels composed of oligo(poly(ethylene glycol) 
fumarate) (OPF)/poly(ethylene glycol)-diacrylate (PEG-DA)/heparin methacrylamide 
(heparin MAm), subsequently placed in a transwell insert, and cocultured with a 
monolayer of osteoblasts. We hypothesized that MSCs cultured in hydrogels with higher 
amounts of heparin would produce higher levels of osteogenic markers over time when 
compared to hydrogels without heparin. Additionally, we hypothesized that coculture of 
encapsulated MSCs with osteoblasts would promote the osteogenic phenotype when 
compared to encapsulated MSCs cocultured with a monolayer of MSCs. In particular, 
alkaline phosphatase activity, calcium accumulation, and histology were evaluated for 
up to 21 days. Furthermore, in order to better understand possible mechanisms behind 
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the results observed, the hydrogels were also characterized for their ability to 
differentially sequester charged model proteins from solution.  
 
3.2 Materials and Methods 
3.2.1 Polymer Synthesis 
Oligo(poly(ethylene glycol) fumarate) (OPF; Mn = 23,900 ± 200 Da, 
polydisperity index (PI) = 4.1  ± 0.1) and poly(ethylene glycol)-diacrylate (PEG-DA; 
Mn = 3,800 ± 20 Da, PI = 1.1  ± 0.0) were synthesized, purified, and stored as 
previously described  [257, 258]. OPF and PEG-DA were analyzed by gel permeation 
chromatography (GPC, Shimadzu GPC and Waters column) to determine molecular 
weight and the polydisperity index. For cell encapsulation studies, the arginine-glycine-
aspartic acid (RGD) adhesion peptide (Peprotech, Rocky Hill, NJ) was conjugated to a 
3400 Da MW acrylated-PEG-succinimidyl valerate spacer (Laysan Bio, Arab, AL) 
according to previous protocols [259].   
In order to allow heparin crosslinking, heparin was modified using N-(3-
dimethylpropyl)-N’-ethylcarbodiimide (EDC) / N-hydroxysulfosuccinimide (sulfo-
NHS) chemistry modified from a previous protocol [260]. N-(3-aminopropyl) 
methacrylamide (APMAm; Polysciences, Warrington, PA) was conjugated to high 
molecular weight heparin sodium salt from porcine intestinal mucosa (17-19kDa, 
Sigma-Aldrich, St. Louis, MO) to form heparin methacrylamide (MAm).  In a solution 
of 0.005 mmol EDC (Sigma-Aldrich) and 0.005 mmol sulfo-NHS (Sigma-Aldrich) in 
dH2O, 1.61 mg/mL heparin sodium salt (~0.00125 mmol GAG by mer MW) was 
combined with 0.005 mmol APMAm. The reaction mixture was incubated at room 
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temperature for 2 h with stirring at pH 5-6. Another round of the above amounts of 
APMAm and EDC were added, and the reaction was allowed to proceed for another 2 h. 
After a total reaction time of 4 h, the mixture was dialyzed against 10 mM NaCl for 1 
day, followed by dH2O for 2 days and then lyophilized (Labconco, Kansas City, MO) 
for 4 days. All polymers were stored at -20°C until use. Structures of polymers used are 
shown in Figure 3.1.   
 
3.2.2 Heparin-Containing Hydrogel Fabrication 
OPF and PEG-DA were used as a mixture of 50:50 by weight in all hydrogels. 
Heparin MAm was incorporated in amounts of 0%, 1%, and 10% weight of total dry 
weight of polymer and subsequently dissolved in PBS (Invitrogen, Carlsbad, CA) with 
0.05% w/w Darocur 2959 (D2959, CIBA Chemicals, Tarrytown, NY) for an initial 
water content of 90% (w/w). Macromer solutions were dispensed in 40 µL amounts into 
PTFE (Teflon) wells and crosslinked under 365 nm UV light (UVP, Upland, CA) at an 
 
Figure 3.1 Polymers utilized in these experiments. (a) Chemical structure of heparin 
methacrylamide (MAm). (b) Chemical structure of oligo(poly(ethylene glycol) 
fumarate (OPF). (c) Chemical structure of poly(ethylene glycol)-diacrylate (PEG-DA).    
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approximate intensity of 10 mW/cm2 for 15 minutes. Resulting hydrogel disks were 6 
mm in diameter and ~1 mm thick.  
3.2.3 Hydrogel Characterization and Heparin Release 
Hydrogel discs containing 0%, 1%, and 10% heparin MAm were fabricated as 
described above and were allowed to swell for 24 h in PBS at 37°C.  The swollen 
hydrogel discs were weighed and subsequently lyophilized for 24 h.  The dry weights 
were measured and the fold swelling ratio of swollen to dry weights (Ws/Wd) were 
calculated.  
To image hydrogels with sulfated GAGs, hydrogels were stained at 2 time points. 
After fabrication, hydrogels were allowed to swell in a solution of 1,9-
dimethylmethylene blue (DMMB; Sigma-Aldrich) for 5 hours with hourly replacement 
of DMMB, rinsed in PBS, and imaged with a digital camera. A second set of hydrogels 
was allowed to soak in PBS for 4 days, with daily replacement of PBS, and thereafter 
stained in a solution of DMMB for 1.5 hours.  
To evaluate the ability of heparin MAm to remain covalently crosslinked in 
hydrogels, a heparin MAm release study was conducted. Hydrogels were fabricated as 
detailed above and placed in 1 mL of PBS. On days 1, 2, 3, and 4 the entire volume of 
supernatant was removed and replaced with fresh PBS. Supernatant volumes were 
recorded and amount of heparin MAm in the supernatant was determined by comparison 
to standards incubated with DMMB and read on a plate reader at 520 nm.  
3.2.4 Human Mesenchymal Stem Cell (MSC) Culture 
Cryopreserved human MSCs were obtained from Texas A&M Health Science 
Center College of Medicine Institute for Regenerative Medicine at Scott & White and 
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were harvested and characterized as described elsewhere [261]. Thawed cells were 
expanded in growth media consisting of alpha-minimum essential medium (α-MEM, 
Mediatech, Manassas, VA) containing 16.3% fetal bovine serum (FBS, HyClone, Logan, 
UT), 1% antibiotic-antimycotic solution (A/A, Mediatech), and 1% 200 mM L-
glutamine (Mediatech). Cells were cryopreserved at passage 3. For encapsulation, MSCs 
were thawed, expanded until 80% confluent, and trypsinized with 0.05% trypsin/EDTA 
(Mediatech). Cells were encapsulated at passage 4 at a density of 10x106 cells/mL.  
3.2.5 Human MSC Encapsulation and Viability Staining 
Heparin methacrylamide (MAm) was incorporated in amounts of 0%, 1%, and 
10% (w/w) in OPF/PEG-DA hydrogels containing 1µmol/g of the RGD peptide 
sequence. Polymers and peptide were dissolved to a final concentration of 10% w/w in 
cell suspension and PBS containing 0.05% w/w D2959. The macromer and cell solution 
was dispensed in 40 µL aliquots and crosslinked for 15 min under UV exposure in 
Teflon molds.  
For viability studies, hydrogels were maintained in cell medium containing 
αMEM, 10% FBS, 1% A/A, and 1% 200 mM L-glutamine. Medium was exchanged 
every 3 days. At days 1 and 21, hydrogels were rinsed for 30 min in sterile PBS and 
subsequently incubated in LIVE/DEAD staining solution (Invitrogen) for 45 min at 
37°C. Hydrogels were rinsed of excess stain and imaged with a confocal microscope 
(LSM 510; Carl Zeiss, Germany) at 3 points on each gel. Three hydrogels for each 
formulation were imaged and z-stacks were collected at 10 µm intervals. Images located 
within the interior of each stack were compared.  
3.2.6 Osteoblast Cell Culture and Coculture with MSC-laden Hydrogels 
! 43 
3.2.6.1 Monolayer cell culture 
Human osteoblasts (Lonza, Walkersville, MD) were expanded for 9 doublings in 
osteoblast growth medium (Lonza) supplemented with osteoblast growth medium 
SingleQuots (Lonza). Osteoblasts were trypsinized and stored frozen in medium, 10% 
FBS, and 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich) until use. Upon thawing, 
cells were seeded into 12-well plates at a density of 10,000 cells/cm2 and allowed to 
proliferate for 4 days in growth medium consisting of low glucose DMEM (Mediatech), 
10% FBS (HyClone), 1% amphotericin B (Mediatech), and 0.1% gentamicin 
(Mediatech). After 4 days in growth medium, osteoblasts were incubated for 3 days in 
osteogenic medium (10% FBS, 1% amphotericin, 0.1% gentamicin, 50 µM L-ascorbic 
2-phosphate sesquimagnesium (Sigma-Aldrich), 10 mM β-glycerolphosphate (Alfa 
Aesar, Ward Hill, MA), and 100 nM dexamethasone (Alfa Aesar)) in order to preserve 
the cell phenotype prior to switching the cells to the coculture medium.  
For coculture with MSC monolayers, passage 4 MSCs were plated at 20,000 
cells/well in 12-well plates 2 days prior to start of the coculture study to allow cells to 
attach and equilibrate from thawing.  
3.2.6.2 MSC Encapsulation  
MSCs were encapsulated in 0%, 1% and 10% heparin MAm hydrogels as 
detailed above. Acellular hydrogels were also fabricated and served as blank controls.  
Blanks and cell-laden hydrogels were placed in 0.4 µm pore transwells (Corning, Lowell, 
MA) and placed over wells of osteoblasts or MSCs. Coculture system medium consisted 
of 10% FBS, 10 mM β-glycerolphosphate, 50 µM L-ascorbic acid 2-phosphate 
sesquimagnesium, 1% amphotericin B and 0.1% gentamicin in low glucose DMEM. 
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Medium was exchanged every 3 days. At day 11, in order to prevent over-confluence of 
cells, MSC and osteoblast monolayers were replaced with cells pre-cultured in the same 
conditions as the original plates. On days 1, 14, and 21, hydrogels (n=3 per culture 
condition) were retrieved, rinsed of medium, crushed with a pellet grinder, suspended in 
750 µl ddH20 and underwent 3 freeze-thaw cycles to lyse cells for assays to quantify 
DNA content, alkaline phosphatase activity, and calcium concentration. Also on day 21, 
hydrogels (n=2 per culture condition) were collected for histology. 
3.2.7 Biochemical Assays for DNA Content, ALP Activity, and Calcium 
Accumulation 
DNA content was quantitatively analyzed over time by the Quant-iT PicoGreen 
dsDNA Assay kit (Invitrogen) per manufacturer’s instructions. Fluorescent output was 
read with a plate reader (SpectraMax M2e; Molecular Devices, Sunnyvale, CA). 
For the ALP assay, in a 96 well plate, 50 µL aliquots of the cell lysates were incubated 
with 100 µl of 20 mM p-nitrophenol phosphate substrate solution (Sigma-Aldrich) and 
50 µL alkaline buffer at 37°C for 60 min. A standard solution was made with a serial 
dilution of p-nitrophenol in ddH2O (Sigma-Aldrich) and similarly incubated with the 
substrate solution and alkaline buffer. The absorbance at 405 nm was read on a plate 
reader and the ALP activity was determined using the standard curve.  
Calcium concentration was determined by reaction of calcium in the samples 
with Arsenazo III (Genzyme Diagnostics, Cambridge, MA), producing a blue-purple 
complex. Homogenized samples were incubated overnight in an equal volume of 1 N 
acetic acid at 37°C. In a 96 well plate, 25 µL aliquots of samples were incubated at room 
temperature with 275 µL of Arsenazo reagent for 10 min. Standard solutions were made 
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by serial dilution of calcium chloride in acetic acid. The absorbance of each well was 
read at 650 nm. Acellular hydrogels were fabricated and cocultured with monolayers of 
osteoblasts or MSCs, similar to cell-laden hydrogels. In all biochemical assays, values 
from acellular hydrogels were subtracted from data values obtained from cell-laden 
hydrogels. Three samples were analyzed for each sample type at each time point.  
3.2.8 Histological Evaluation of Mineralization 
At day 21 of the coculture experiment, hydrogels were fixed in 10% neutral 
buffered formalin for 2 hours and stored in 20% sucrose solution overnight at 4°C. 
Samples were embedded in a 50:50 ratio of optimum cutting temperature (Sakura 
Finetek, Torrance, CA) compound:20% sucrose by volume, placed in a vacuum chamber 
for 4 h to increase penetration of embedding material into samples, and flash frozen in 
liquid nitrogen. Histological sections of 10 µm thick slices were obtained from a cryostat 
(HM 560 Cryo-Star; Microm, Germany) and stained with von Kossa stain. Briefly, 
sections were incubated in a 5% solution of silver nitrate (Sigma-Aldrich) in ddH20 for 
15 min under a UV lamp. Slides were washed with ddH20 and unreacted silver nitrate 
was removed by incubating sections with 5% sodium thiosulfate for 3 min. Sections 
were counterstained with eosin. Slides were examined by light microscopy (Eclipse 
TE2000-U, Nikon, Melville, NY).  
3.2.9 Cell Density on Hydrogel Surfaces 
On days 1 and 21 of coculture, hydrogels were rinsed with PBS and placed in 
solutions of 0.01 ng/mL Hoechst 33258 stain (Invitrogen) in PBS for 2 h in an incubator. 
Hydrogels were imaged from the surface down to 200 µm below the surface by 
collecting z-stacks at an interval of 10 µm on a confocal microscope (Zeiss 510 NLO 
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META). Z-stacks were projected into a 2-dimensional image and analyzed for cell 
number by counting nuclei in ImageJ (NIH, Bethesda, MD). 
3.2.10 Model Protein Absorption into Heparin-containing Hydrogels 
To examine the electrostatic interaction between charged proteins with heparin-
containing hydrogels, negatively-charged casein (MW=19-24 kDa; Sigma-Aldrich) and 
positively-charged histone from calf thymus (MW=11-21 kDa; Sigma-Aldrich) at pH 
7.4 were conjugated to fluorescein isothiocyanate (FITC, Acros Organics). 100 mg of 
protein was dissolved in 25 mL of bicarbonate buffer solution at pH 8.3. A total of 1.25 
mL of a 2 mg/mL FITC solution in DMSO was slowly dropped into the protein solution 
and 70.2 mg of ammonium chloride (Sigma-Aldrich) was added to the reaction. The 
reaction was allowed to proceed for 8 h at 4°C protected from light. The conjugated 
protein solutions were then dialyzed against ddH20 for 4 days.  
Hydrogels containing 0%, 1%, and 10% wt. heparin were fabricated and allowed 
to swell in PBS overnight. Hydrogels were then placed into 24-well plates with 1 mL of 
FITC-conjugated protein solution for 1 day. For confocal imaging, each hydrogel was 
taken directly from the protein solution and placed in the cell chamber containing PBS 
for immediate imaging. Three spots per hydrogel and 3 gels per condition were imaged. 
All microscope settings (master gain=670, digital gain=1.0, digital offset=-1.68, 
pinhole=94 µm, and laser=488 nm, 3%) were maintained across all samples. The 
average fluorescence value for each layer of the stack was computed and compiled in 
MATLAB (Mathworks, Natick, MA). In order to average the 3 stacks from each 
hydrogel, a MATLAB algorithm was created to align the maximum fluorescence value 
of each stack. The relative fluorescence value was then averaged from the 3 stacks at 
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each depth through the hydrogel, resulting in an average curve for each hydrogel. The 
average fluorescence values over the 3 hydrogels for each condition were computed 
similarly. Statistical analysis was performed on predetermined depths and limited to less 
than half of the hydrogel thickness, as the ability to collect data past a depth of 600µm 
was attenuated when z-stacks were collected. 
3.2.11 Statistical Analysis 
Results are displayed as mean ± standard deviation. ALP activity and calcium 
data were transformed with the Box-Cox transformation for analysis. Data were 
analyzed by one-way, two-way, and/or three-way analysis of variance to identify groups 
with significant differences and interactions. Tukey’s post hoc with the significance 
level set at p<0.05 indicated significant differences between individual samples. 
Statistical analysis was performed with Systat Software (Chicago, IL). 
 
3.3 RESULTS 
3.3.1 Hydrogel Characterization and Heparin Release 
Hydrogels formed robust gels after 15 min of UV exposure and the addition of 
up to 10% wt. heparin did not statistically affect the swelling ratio of the hydrogels 
(Figure 3.2a). There was a slightly deeper staining observed in the 10% wt. heparin 
MAm hydrogels versus the 1% heparin formulations when hydrogels were allowed to 
swell in DMMB for 5 hours after fabrication. The 0% wt. heparin hydrogels did not 
exhibit staining characteristic of GAG incorporation. Additionally, after 4 days in PBS 
(replenished daily), the 10% wt. heparin hydrogels were obviously stained a deep purple, 
confirming that greater amounts of sulfated heparin were present within this formulation 
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after removal of any uncrosslinked fractions (Figure 3.2a, bottom row). In addition, the 
staining also appeared to suggest that sulfated heparin was distributed relatively 
uniformly throughout the hydrogels and clear differences existed between hydrogel 
types even after 4 days of soaking in PBS. Release of uncrosslinked heparin MAm from 
the hydrogels occurred in a burst release at 1 day, with little additional release thereafter 
(Figure 3.2b). By day 4, the cumulative percent released from 1% and 10% wt. heparin 
MAm hydrogels were not significantly different.   
LIVE/DEAD staining revealed that MSCs encapsulated in 0%, 1%, and 10% wt. 
heparin MAm hydrogels were predominately viable throughout the hydrogel thickness 
and viability was comparable between day 1 and day 21 (Figure 3.3). 
 
!
Figure 3.2 Heparin MAm can be covalently integrated within hydrogels without 
affecting the swelling ratio and with minimal release of heparin MAm from hydrogels 
over time. (a) Fold swelling of 1% and 10% wt. heparin MAm/wt. polymer hydrogels 
were not significantly different than fold swelling of hydrogels without heparin MAm 
(p>0.05, n=4±S.D.). DMMB staining of hydrogels at 5 hours and 4 days after 
fabrication showed more intense staining with incorporation of increasing amounts of 
heparin MAm. Scale bar=5 mm. (b) The cumulative release of uncrosslinked heparin 





3.3.2 Biochemical Assays for DNA Content, ALP Activity, and Calcium 
Accumulation 
DNA retrieved from hydrogels on day 21 showed that the DNA level from 0% 
wt. heparin MAm hydrogels cocultured with MSCs was significantly lower than the 
DNA content of 10% wt. heparin MAm hydrogels also cocultured with MSCs (Figure 
3.4). In comparison between coculture types, 10% wt. heparin MAm hydrogels 
cocultured with MSCs had a higher DNA content than 10% wt. heparin MAm hydrogels 
cocultured with osteoblasts. Within the osteoblast coculture group, all hydrogels had 
statistically different DNA content from each other. In all samples, there was a 
significant decrease in DNA content by day 21 either from day 1 or day 14 (data not 
shown).   
 
 
Figure 3.3 Human mesenchymal stem cells (hMSCs) remain viable in heparin MAm-
functionalized hydrogels for 21 days. Live cells are stained green and non-viable cells 
are stained red. Scale bar=100µm!
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When in coculture with osteoblasts, the MSCs encapsulated in 0%, 1%, and 10% 
wt. heparin MAm hydrogels exhibited significantly higher ALP activity on day 1 than 
samples cocultured with MSCs (Figure 3.5a). This trend continued until day 21, with all 
samples cocultured with osteoblasts exhibiting higher ALP activity than the same 
hydrogel type cocultured with MSCs at the same time point. While the MSCs 
encapsulated in the 1% wt. heparin MAm hydrogels did not exhibit any change in ALP 
activity over time, the cells in the 0% wt. heparin MAm hydrogels showed either no 
change (when cocultured with MSCs) or a decrease (when cocultured with osteoblasts) 
between day 1 and 21. With MSCs encapsulated in 10% wt. heparin MAm hydrogels, 
ALP activity increased over time when cocultured with osteoblasts resulting in a 5-fold 
increase from day 1 to day 21. This sample exhibited the highest ALP activity compared 
to all samples on day 21. Conversely, ALP activity decreased with time for MSCs in 
10% wt. heparin MAm samples cocultured with MSCs.    
!
Figure 3.4 DNA content from cocultured hydrogels on day 21 show no significant 
differences between MSC and osteoblast cocultures in 0% and 1% wt. heparin 
hydrogels. There is a significant decrease in DNA quantified in 10% wt. heparin MAm 
hydrogels cocultured with osteoblasts compared to all other hydrogels cocultured with 
osteoblasts. * designates a significant difference (p<0.05, n=3±S.D.) between 
indicated samples.     
!
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 Little to no calcium accumulation was observed in all samples on day 1 of 
coculture, but by day 21, the 1% and 10% wt. heparin MAm cell-laden hydrogels 
accumulated significantly more calcium when cocultured with osteoblasts compared to 
MSC coculture controls (Figure 3.5b). By day 21, the 10% wt. heparin MAm samples 
cocultured with osteoblasts showed an over 50-fold increase in calcium content from 
!
Figure 3.5 10% heparin MAm hydrogels with encapsulated MSCs and cocultured with 
osteoblasts show marked alkaline phosphatase (ALP) activity and calcium 
accumulation by day 21 compared to other hydrogel formulations. (a) Higher ALP 
activity was observed for hydrogels cocultured with osteoblasts compared to coculture 
with MSCs. Hydrogels containing 10% wt. heparin MAm showed significantly higher 
ALP activity than other hydrogel types by day 21 (p<0.05, n=3±S.D.). Note different 
scales for y-axes. (b) Calcium accumulation increased over time for each hydrogel 
type, with 10% MSC:OB showing the highest calcium concentration by day 21 
compared to all other samples besides 1% MSC:OB (p<0.05, n=3±S.D.). Note 
different scales for y-axes. * indicates significant difference from MSC:MSC 
coculture at the same day and hydrogel type; # designates significant difference 
between indicated samples.  
!
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day 14 and was significantly higher than the MSC coculture controls on the same day.  
Encapsulated MSCs cocultured with MSCs did not exhibit any large differences in 
calcium accumulation between hydrogel types until day 21, when calcium accumulation 
was greatest in the 10% wt. heparin MAm hydrogels (Figure 3.5b). Differences between 
osteoblast and MSC cocultures were not observed for 0% and 1% wt. heparin MAm 
samples until day 21, when samples cocultured with osteoblasts showed marked increase 
over samples cocultured with MSCs. MSCs in 10% wt. heparin MAm hydrogels initially 
showed slightly higher calcium amount in samples cocultured with MSCs, but by day 14, 
samples cocultured with osteoblasts showed significantly higher calcium accumulation.  
3.3.3 Histological Evaluation of Mineralization 
Histological evaluation of hydrogels after 21 days of coculture by von Kossa 
staining shows cell-associated mineral accumulation in all samples, regardless of 
coculture conditions (Figure 3.6). Mineral accumulation also occurred on the edges of 
1% and 10% wt. heparin MAm hydrogels cocultured with osteoblasts, with more intense 
mineral staining in the 10% wt. heparin MAm samples (Figure 3.6e). Mineral deposition 
was also observed for the 10% wt. heparin MAm hydrogels cocultured with MSCs, 
although to a lesser extent (Figure 3.6f).  
3.3.4 Cell Density on Hydrogel Surfaces  
There were no significant differences in cell density on all cocultured hydrogels 
on day 1. Counting cells on the surface of hydrogels cocultured with MSCs and 
osteoblasts at day 21 revealed that the cell density on 10% wt. heparin MAm samples 
was not significantly different between coculture types. Additionally, the cell density on 
10% wt. heparin MAm hydrogels was lower than on 0% wt. heparin hydrogels and not 
! 53 
significantly different than the number of cells on the surface of 1% wt. heparin 
hydrogels (data not shown).  
 
3.3.5 Model Protein Absorption into Heparin-containing Hydrogels 
In this study, model proteins, casein and histone, were chosen for their respective 
negative and positive overall charge at pH 7.4. Confocal images showed that casein and 
histone have different profiles within the hydrogels and across the varying amounts of 
heparin MAm. Casein was distributed relatively uniformly throughout the hydrogel 
thickness in all hydrogel formulations (Figure 3.7a-c). Histone displayed a more uniform 
distribution in the 0% wt. heparin MAm samples, but appeared more localized to the 
!
Figure 3.6 Mineralization occurs pericellularly, with additional surface mineralization 
on the 10% heparin hydrogels. Histological sections showing mineralization (stained 
black) of 0% (a-b), 1% (c-d), and 10% (e-f) wt. heparin MAm hydrogels cocultured 
with osteoblasts (a, c, e) and MSCs (b, d, f) on day 21. All samples exhibited cells 
with mineralization within the interior of the hydrogels (black arrows). The 1% and 
10% wt. heparin MAm samples cocultured with osteoblasts exhibited mineralization 
on the periphery of the hydrogels (c,e, white arrow).  The 10% wt. heparin MAm 
samples cocultured with MSCs showed peripheral staining to a lesser degree (f). Insets 
show magnification of representative edges of the hydrogels. Scale bar=100µm  
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surface of the hydrogels in 1% and 10% wt. heparin MAm samples (Figure 3.7d-f). The 
protein intensity in the 0% wt. heparin MAm hydrogels was similar across depth of the 
hydrogel for both casein and histone (Figure 3.7g). However, with 1% and 10% wt. 
heparin MAm, the histone fluorescence decreased with increasing depth into the 
hydrogel, with a more precipitous decrease in intensity with depth in the 10% wt. 
heparin MAm hydrogels (Figure 3.7h, i). In 10% wt. heparin MAm hydrogels, the same 
fluorescence intensity was collected for both casein and histone within the first 100 µm 
!
Figure 3.7 Negatively and postively-charged proteins have different absorption 
profiles into 0%, 1%, and 10% wt. heparin MAm hydrogels. FITC-casein was 
absorbed into the entire thickness of the hydrogels across all heparin amounts (a-c). 
FITC-histone was absorbed into the entire thickness of the 0% wt. heparin MAm 
samples (d), but only penetrated a small fraction of the 1% and 10% wt. heparin MAm 
samples (e,f). Column graphs show average intensity of labeled proteins at specified 
depths across 0%, 1%, and 10% wt. heparin MAm hydrogels (g-i). # indicates that the 
casein intensity is significantly higher than the histone intensity at the same depth and 
heparin content; ## indicates that the intensity is lower than the casein intensity at the 
corresponding depth in the 0% wt. heparin MAm hydrogels; * indicates difference 
from all other histone intensity measurements in the same hydrogel type; ** indicates 
difference in histone intensity from the other hydrogel types at the same depth; *** 
indicates that the histone intensity is different than the histone intensity at the same 
depth in the 1% wt. heparin MAm hydrogels.  
!
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of the hydrogel, but the average histone intensity dropped close to 0 with increasing 
depth. Alternatively, casein intensity remained relatively uniform throughout the 
analyzed depth.  
 
3.4 DISCUSSION 
Coculture systems may help achieve certain phenotypes or level of 
differentiation prior to transplantation for stem cell-based therapies [151, 262]. Here, 
MSCs were cocultured with osteoblasts as a proof-of-concept study in order to better 
understand the role of the biomaterial environment in priming stem cells in coculture 
with native, differentiated cells. In the present study, cells remained viable in all 
hydrogel formulations through 21 days of culture (Figures. 3.3 and 3.4), but the 
interaction of heparin-containing biomaterials and osteoblast-mediated paracrine 
signaling significantly promoted the differentiation of MSCs toward the osteogenic 
lineage.  
In these experiments, cells were encapsulated within hydrolytically degradable 
hydrogels that show little degradation over the study period [263], which may prevent 
cell proliferation and induce a rounded cell morphology. However, these materials were 
chosen because previous research has shown similar materials to have the appropriate 
mesh size (Å to nm) to allow diffusion of nutrients for cell encapsulation [264, 265], 
while preventing potential confounding factors for this study, such as cell spreading. The 
high viability and number of cells (Figure 3.3) observed in all samples is in concurrence 
with previous studies of encapsulated cells [251, 266-269]. There were no differences in 
the DNA content of hydrogels between coculture type within the 0% and 1% wt. heparin 
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hydrogel formulations on day 21 (Figure 4.4), indicating that DNA content was not a 
factor in the differences observed in the bioassays. Although less DNA was observed in 
the 10% wt. heparin MAm hydrogels cocultured with osteoblasts compared to other 
hydrogel types (Figure 4.4), this may be attributed to the increased mineralization in 
these hydrogels, which can hinder DNA diffusion out of the gel for subsequent 
quantification [263].   
The absence of significant differences in fold swelling up to 10% dry wt. heparin 
MAm suggests similar mesh sizes between hydrogel types [270], which implies that 
there are relatively minor differences in mechanical properties and transport through the 
network between these formulations [271]. Non-crosslinked heparin MAm in hydrogels 
is primarily released by day 1, which precludes any long-term effects of soluble heparin 
in the system. Therefore, the biological results observed from these experiments can be 
primarily attributed to increasing amounts of heparin incorporated into the hydrogels. 
Increasing amounts of heparin in hydrogels have been shown to reduce release of 
positively-charged growth factors (Supplementary figure A.1), and may play a role in 
sequestering soluble factors from the coculture environment. 
In this study, a 3D hydrogel environment was investigated as a means to expose 
a relatively large number of MSCs to a much small number of cells in monolayer. For 
these experiments, the number of MSCs originally encapsulated was approximately 5 
times greater than the osteoblasts used in each cocultured sample. Past studies have 
shown increased osteogenic markers such as ALP activity by day 14, but use of twice 
the number of osteoblasts compared to MSCs may have accelerated the differentiation in 
that coculture study [151]. The results in this study suggest that a smaller pool of 
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differentiated cells can successfully be used to prime a larger population of MSCs, 
which could be important when ex vivo expansion of a differentiated cell type is limited.  
Results demonstrate an increase in ALP activity, particularly in the 10% wt. heparin 
MAm hydrogels cocultured with osteoblasts, which suggests that MSCs differentiated 
toward the osteogenic lineage. ALP is one marker for osteoblastic differentiation and 
indicates the capacity for cells to produce a mineralized matrix [140, 151]. In this study, 
the elevated ALP activity observed in samples cocultured with osteoblasts suggests that 
heparin interacted with osteoblast-secreted factors to mediate MSC-directed ALP 
production not seen in acellular controls. In a prior study, increased bone-related gene 
expression as well as increased calcium staining by alizarin red in MSCs by 3 weeks 
have been shown in cocultures involving monolayers of MSCs and osteoblasts [152]. In 
the present study, an increase of ALP activity by day 21 for the coculture with 
osteoblasts is comparable in timescale.  
It has been found that ALP production is stimulated by BMP-2 administration 
and regulated through the canonical Wnt pathway [272]. The presence of members of 
the BMP family is likely in our coculture system since it has been established that 
osteoblasts can secrete BMP-2, BMP-4, and BMP-7, which are known to induce 
osteogenesis in MSCs [273, 274]. Furthermore, previous research has shown that 
specific BMP interaction with heparin results in the augmentation of the biological 
activity of BMPs, as reflected in the production of mineralized tissue or induction of 
osteoblastic differentiation of MSCs [34, 249, 275], which makes these hydrogel 
formulations particularly suited to enhancing pro-osteogenic signaling from nearby cells. 
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Calcium deposition, a late marker that indicates the capacity for cell-mediated 
matrix mineralization [276], on day 14 was greatest in the 10% wt. heparin MAm 
samples cocultured with osteoblasts, but by day 21 all samples cocultured with 
osteoblasts exhibited greater calcium accumulation over their MSC cocultured 
counterparts (Figure 3.5). Calcium accumulation was higher in samples cocultured with 
osteoblasts even after subtraction of calcium values from acellular controls, suggesting 
that the increase in calcium is at least partially cell-mediated by MSCs or the crosstalk 
between MSCs and osteoblasts.  
Mineralization, as evidenced by von Kossa staining was evident around cells 
throughout all samples with more intense staining on the edges of 1% and 10% wt. 
heparin MAm hydrogels cocultured with osteoblasts (Figure 3.6). Previously, MSCs 
have been shown to differentiate and mineralize in PEG-based hydrogels in the presence 
of osteogenic medium, including the glucocorticoid dexamethasone [277]. In order to 
unmask the signaling that can occur between MSCs and osteoblasts, dexamethasone was 
not used in our coculture system, but increases in ALP activity and mineralization were 
still observed in the hydrogels. The coculture medium did include β-glycerolphosphate, 
a source of phosphate, which has been shown to be necessary to initiate mineralization 
[278] yet does not greatly increase the expression of bone proteins such as bone 
sialoprotein and osteocalcin in a manner like dexamethosone  [279]. Mineralization was 
not observed on the surface of 0% wt. heparin MAm hydrogels and were not as heavily 
mineralized in MSC controls at higher heparin amounts, indicating that the presence of 
heparin may affect the level of mineralization observed, but cell mediation of 
mineralization is also necessary, as evident in this study. Similarly, there was no 
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significant difference between cell density on the 10% wt. heparin MAm hydrogels 
cocultured with MSCs or osteoblasts at either day 1 or 21 of culture, indicating that the 
extra mineral observed on the surface of samples cocultured with osteoblasts was not 
due to additional cells on the surface.   
Although the mechanism is unknown, previous research has shown evidence that 
heparin can prevent mineralization in differentiating cells [219, 280], in contrast to the 
results presented here. These prior studies utilized soluble or adsorbed heparin, which 
may be removed upon media changes, along with any biomolecules that may have 
complexed with them. The level of soluble heparin concentration has been shown to 
have a biphasic effect on mineralization [281], but it is not known how mineralization is 
affected by covalently bound heparin as used in this study. Benoit et al. showed that 
osteogenic differentiation of MSCs was possible in heparin-functionalized PEG 
hydrogels, possibly due to integrin engagement or BMP binding [251]. Additionally, the 
interaction between heparin and extracellular proteins, such as collagen and fibronectin, 
may improve mineralization in heparin-containing materials [282, 283].  
Heparin has been shown to have increasing affinity for positively-charged 
proteins with increasing chain length and sulfation [284]. In this experiment, high 
molecular weight heparin was used and the DMMB assay revealed that sulfated 
molecules were retained in the hydrogels, suggesting that high affinity may exist 
between secreted soluble factors and heparin in the coculture system. Although it was 
expected that electrostatic interactions between protein and heparin could occur 
uniformly throughout the entire hydrogel thickness, it was observed that the presence of 
heparin reduced diffusion of positively-charged molecules, such as the model protein 
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histone, into the hydrogel, particularly in the 10% wt. heparin MAm formulation (Figure 
3.7). This phenomenon was not observed when hydrogels were allowed to absorb the 
similarly sized, negatively-charged protein casein. Molecular transport is often limited 
by molecular size, but there is emerging research on the filtering effects of charged 
extracellular matrix (ECM) molecules that may act as an electrostatic bandpass [285]. 
An in vivo study has shown that the presence of heparan sulfate in the ECM can 
decrease the effective diffusion coefficient of polyanion-binding lactoferrin through 
tissues by ~60% [286], indicating that the effective charge of heparin can affect the 
diffusion of charged molecules in our system. These studies correlate well with our 
observations of positively-charged histone sequestration primarily to the surface of 
heparin-containing hydrogels.  
For future design of biomaterials to “capture” soluble signals from the medium 
or another nearby cell type, results from our studies suggest that surface, rather than bulk, 
biomaterial modification methods may be all that is required at high amounts of heparin. 
Additionally, the overall heparin amount incorporation can be reduced to allow more 
uniform transport of soluble factors in hydrogels of thickness on the order of 1 mm or 
greater. Results from our study between charged proteins and heparin-containing 
hydrogels also have implications in creating new biomaterials to exclusively “capture” 
and localize positively-charged proteins for future studies in growth factor presentation 
to cells or in creating soluble factor gradients.  
While further work is required to elucidate the particular factors that bind to the 
heparin hydrogels and the effect of soluble factor transport through heparin-containing 
hydrogels on uniform priming and extent of differentiation of cells, our results are 
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encouraging for the use of GAG-based biomaterials to tune the responsiveness of cells 
in coculture and holds promise as a means of priming a large population of stem cells 
with only a small biopsy. Prior research has shown that pre-culture can instruct in vivo 
differentiation and improve clinical outcome, and our studies represent a potent method 
to prime MSCs, especially when control over the extent of differentiation is desired [241, 
242, 244, 287]. As such, the ability to prime a large population of cells by employing 
GAG-based biomaterials and in conjunction with a smaller pool of differentiated cells is 
an attractive method that could greatly increase the feasibility of using autologous cells 
for orthopaedic tissue engineering and regenerative medicine.   
 
3.5 Conclusions 
Overall, these studies capitalize on the ability of heparin to bind charged soluble 
factors for a novel approach to priming stem cells. MSCs encapsulated in higher 
amounts of heparin exhibited elevated levels of osteogenic markers when cocultured 
with osteoblasts in the absence of dexamethasone. Increase in ALP activity, calcium 
accumulation, and surface mineralization over 21 days was most drastic in 10% wt. 
heparin MAm hydrogels cocultured with osteoblasts, suggesting that the biomaterial 
composition can modulate differentiation of MSCs exposed to paracrine signals from 
nearby osteoblasts. In the future, these proof-of-concept studies will be instructive in 
developing a framework for a biomaterial-based stem cell priming system with various 
other differentiated cell types. As demonstrated here, the ability to promote paracrine 
signaling between cells in the expansion phase via biomaterial carrier design has 
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exciting implications in the field of regenerative medicine, particularly for cases when 
























PRESERVATION OF BMP-2 BIOACTIVITY BY SOLUBLE HEPARIN 
DEPENDS ON SULFATION LEVEL 
 
4.1 Introduction 
Bone morphogenetic proteins (BMPs), members of the transforming growth 
factor (TGF)-β superfamily, were first identified as a component of decellularized and 
demineralized bone matrix that had bone-forming capabilities [159, 160]. They were 
subsequently shown to be sufficient in inducing cartilage and heterotopic bone in vitro 
and in vivo [161, 162]. In developing limbs, BMP-2 is expressed in the mesenchyme 
surrounding early cartilage condensation and may play roles in cell recruitment and 
differentiation of cells into chondrocytes [164]. Additionally, BMP-2 can accelerate the 
transition of proliferating chondrocytes to hypertrophy [288]. 
Participation in bone and cartilage formation has made BMP-2 attractive for 
tissue regeneration applications. It is currently available as a therapeutic protein and an 
absorbable collagen sponge has been approved as its carrier for spinal fusion, open tibial 
fractures, and sinus augmentation [172, 173]. However, BMP-2 has low affinity toward 
collagen, leading to diffusion out of the scaffold and into off-site areas [28]. 
Additionally, BMP-2 has been shown to have a short half-life, suggesting a lower 
potency for the overall therapeutic in vivo [174]. To counter this, delivery vehicles are 
often loaded with supraphysiological doses of BMP-2, which increases overall costs and 
has been shown to cause adverse effects [29, 172, 175]. An ideal therapeutic would limit 
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diffusion out of the scaffold to prevent offsite side-effects and prevent loss of BMP-2 
bioactivity to improve clinical efficacy and lower costs. 
Heparin, a highly sulfated glycosaminoglycan (GAG), can bind many growth 
factors, either electrostatically or through carbohydrate specific sequences. This feature 
makes it an attractive biomaterial to reduce burst release. However, heparin is used 
clinically as an anti-coagulant [289], which may limit its use in vivo unless the anti-
coagulant aspect is ablated. Although it was shown that selective desulfation of heparin 
can significantly reduce the anti-coagulant activity of heparin [290, 291], heparin 
desulfation may impact the interactions between heparin and proteins. The specific 
heparin binding to fibroblast growth factor (FGF) -1 and -2 has been studied extensively 
and was shown to protect FGF from acidic, enzymatic and high temperature conditions 
[205, 208, 292]. It was found that N- and 2-O sulfation on heparin aided binding of 
heparin to FGF-2, but the 6-O sulfate group was needed to stimulate the FGF receptor 
for FGF-induced cell signaling [199]. Removal of these specific sulfation patterns 
reduced FGF-induced signaling. In contrast to these studies, how the role of sulfation 
level and sulfate arrangement on heparin affects the bioactivity of bone morphogenetic 
protein (BMP)-2 has not been as well established, despite the use of BMP-2 in clinical 
applications. 
To date, the protective effects of desulfated heparin derivatives on BMP-2 when 
exposed to denaturing environments have not been elucidated. Unlike FGF-2, which 
requires heparin for signaling, BMP-2 has a heparin-binding domain removed from the 
active site of the protein [168]. And unlike other TGF-β factors, this heparin-binding 
region is not covalently attached to the protein core by disulfide bonds, making this 
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region relatively flexible [177]. This flexibility has been implied to be advantageous in 
binding the heterogeneous structures of heparin or the structurally similar heparan 
sulfate [177, 178]. Understanding the interactions between desulfated heparin 
derivatives and BMP-2 can help develop safe and effective delivery systems.  
Bacterial expressed recombinant proteins commonly exhibit a lack of 
glycosylation compared to mammalian expressed proteins. Glycosylation can confer 
benefits in terms of improved solubility and pharmacokinetics, but the glycosylation of 
recombinant proteins expressed in eukaryotic cells remain difficult to control and 
reproduce [293]. While protein expression from E. coli systems lack the glycosylation 
machinery, it has the benefit of being procedurally simple, rapid, cost efficient, and 
well-characterized [294, 295]. In addition, these non-glycosylated proteins are suitable 
for studies that probe how the protein backbone may be affected by external factors, 
without the confounding effects of glycans.  
The objective of Specific Aim II was to evaluate how the level of sulfation on 
heparin affects the stability of BMP-2 when exposed to thermal stress. Three desulfated 
derivatives were evaluated: N-desulfated (Hep-N), 6-O,N-desulfated (Hep-N,-6O), and 
completely desulfated heparin (Hep-). The hypothesis of this study was that soluble 
complexes formed between heparin and BMP-2 can protect BMP-2 against thermal 
denaturation, and that this protection varies with the sulfation level on the heparin 
molecule. Using an established cell-based bioactivity assay, the bioactivity of non-
glycosylated BMP-2 was evaluated following exposure to high temperature over 15 
minutes in order to probe the effect of co-delivery of heparin derivatives. Interactions 
with desulfated heparin derivatives were further probed by measuring the thermal 
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stability of a positively-charged model protein, histone, when heated over 31-81°C in 
differential scanning fluorimetry.  
4.2 Materials and Methods 
4.2.1 Heparin Modifications and Characterization 
4.2.1.1 Heparin Desulfation to Hep-N and Hep-N,-6O 
Heparin sodium salt from intestinal mucosa (Sigma-Aldrich) was desalted by 
passing a ~10mg/mL solution of heparin in ddH2O through an ion exchange column. 
Dowex 50WX4 resin (mesh size 100-200, Sigma-Aldrich) was dispersed in ddH2O and 
poured into a preparative column (460mm effective length, 10mm internal diameter, 
Ace Glass) with a sealed fritted disc (70-100µm) and glass stopcock at the outlet. The 
resin was washed with ddH2O until the supernatant ran clear. The heparin solution was 
added slowly to the resin and collected in a 500mL round bottom flask. After all the 
heparin solution was poured through, the column was washed with an additional 2 
lengths of water. Adding pyridine in 2mL increments, the pH of the desalted heparin 
was increased to ~6. Excess water and pyridine was evaporated on rotary evaporator 
(Buchi). The solution of heparin pyridine was then dialyzed for 3 days, flash frozen in 
liquid nitrogen, and lyophilized to a powder. 
For Hep-N production, heparin pyridinium salt was dissolved at 1mg/mL in a 
90% DMSO/10% ddH2O solution [290, 296]. The mixture was stirred in a round bottom 
flask at 50°C for 2h using a water bath. The solution was then cooled on ice and 
precipitated by an equal volume of 95% ethanol (VWR) saturated with sodium acetate 
(VWR). The precipitate was centrifuged and supernatant decanted. The precipitate was 
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washed once more with ethanol prior to mixing with dH2O. The solution was dialyzed 
for 3 days with daily exchanges of dH2O and then lyophilized.       
For Hep-N,-6O synthesis, a solution of 10mg/mL of heparin pyridine was made in 
90% N-methylpyrrolidone (NMP, Acros Organics)/10% ddH2O [301]. The solution was 
mixed in a round bottom flask and heated to 90°C on a heating mantle for 48h. The 
solution was then cooled on ice and precipitated with 95% ethanol saturated with 
sodium acetate. The precipitate was stirred for an additional 2h on ice and then 
centrifuged to remove excess ethanol and H2O from heparin. The resulting powder was 
dissolved in H2O and dialyzed for 3 days prior to lyophilization.  
4.2.1.2 Heparin Desulfation to Hep- 
Nonselective desulfation was carried out with a protocol adapted from Kantor 
and Schubert [297]. Heparin sodium salt was stirred at 5.0mg/mL in methanol (VWR) 
containing 0.5% v/v acetyl chloride (Acros Organics). The dispersion was centrifuged 
and acidic methanol was replaced on days 1, 3, and 6 to produce a methyl ester of 
heparin. The product was then dissolved in 20mL dH2O per gram of heparin before 
precipitation in an excess of 95% ethanol while on ice. The methyl ester of heparin was 
centrifuged and washed in ethanol twice. In the last wash, the methyl ester was 
precipitated with ethyl ether (Fisher) and vacuum dried at <5mmHg.  
The methyl ester of desulfated heparin was demethylated at 25mg/mL in 0.1M 
potassium hydroxide (KOH) for 24h to produce Hep-. The Hep- product was then 
neutralized in 4mL of 100mg/mL potassium acetate (Fisher) in 10% v/v acetic acid 
(VWR) per gram of starting product, and precipitated in an excess of ethanol on ice. 
Hep- was washed in ethanol and ethyl ether, vacuum dried, and stored at -20°C until use.  
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4.2.1.3 Material Characterization 
Removal of sulfate groups in all desulfation protocols was confirmed by 
dimethylmethylene blue (DMMB) assay for sulfated GAGs [298]. The absorbance of 
DMMB at 520nm was measured for increasing concentrations of heparin derivatives. 
The absorbance values for 4.5µg/mL heparin derivatives were normalized to the 
absorbance value of native heparin at the same concentration to compute relative 
sulfation levels. 
The molecular weights of heparin derivatives were approximated by gel 
permeation chromatography. Samples were dissolved in an aqueous buffer of 150nM 
magnesium sulfate (Macron Fine Chemicals) and 10mM Tris base (Sigma-Aldrich) in 
ddH2O. The aqueous buffer was also used as the mobile phase in the gel permeation 
chromatography instrument equipped with a refractive index detector  (Shimadzu). 
Samples were injected into the column (Tosoh Bioscience) at a flow rate of 0.5mL/min 
(n=3). Retention times were compared to those produced by polyethylene oxide 
standards in the range of Mp 14,000-73,500 (Waters).   
Proton nuclear magnetic resonance (1H NMR) was utilized to determine the 
shifts observed after each selective desulfation process. Heparin and its desulfated 
derivatives were solubilized in deuterated water (D2O) and 1H NMR was measured on a 
Bruker Avance III 400 spectrometer at 400MHz. The resulting spectra were analyzed by 
calibrating the signal between 5.15 and 5.55ppm, which corresponds to the combined 
signals of H1 from all the glucosamine and uronic acid residues. This provided an 
internal standard which allowed monitoring of the amount of modification to specific 
protons near sulfation sites.   
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4.2.2 Cell-Based Bioactivity Assay 
4.2.2.1 C2C12 Cell Culture 
The mouse myoblast subclone C2C12 cell line (CRL-1772) was purchased from 
ATCC and plated onto a recovery plate in growth medium consisting of 4.5g/mL 
glucose Dulbecco’s Modified Eagle Medium (DMEM, Cellgro), 10% v/v fetal bovine 
serum (FBS, Atlanta Biologics), 1% v/v 10,000IU penicillin/10,000µg/mL streptomycin 
(Mediatech), and 1% v/v 200mM L-glutamine (Cellgro). Plate was subcultured with 
0.05% trypsin with ethylenediaminetetraacetic acid (EDTA) before reaching confluency 
to prevent depletion of myoblastic population in the culture and replated at 1.5x105-
1.0x106 cells/75cm2. All studies were performed with cells between passages 4-6. 
4.2.2.2 BMP-2 Administration and Heat Treatment 
Recombinant human BMP-2 expressed in E. coli (Peprotech, 26kDa) was 
resuspended at 100µg/mL in sterile ddH2O and single-use aliquots were frozen until use. 
Solutions of 1mg/mL heparin and desulfated heparin derivatives were made in PBS, 
filter sterilized, and aliquots were frozen until use. Low adsorption tubes (Eppendorf) 
were used for storage of BMP-2 and heparin.    
In preparation of BMP-2 bioactivity, 2x104 C2C12 cells were plated into each 
well of a 96-well plate in growth medium. Cells were allowed to attach for 8h, at which 
point, cells were washed with PBS containing 1g/L CaCl2/MgCl2 and switched to the 
bioactivity assay medium. BMP-2 concentrations were tested at 0-600ng/mL; all 
bioactivity studies presented here used 500ng/mL, or 150ng/well, BMP-2. Heparin was 
assumed to have a molecular weight of 18kDa and molar excess of 10 and 100 were 
used in the studies. Due to the polydisperse nature of the modified heparin species, 
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equivalent mass concentrations of heparin derivatives were used in the studies. For 
samples consisting of heparin or heparin derivatives, BMP-2 and heparin were pipetted 
vigorously before being allowed to incubate at room temperature for 10min to allow 
interaction between the moieties. Samples for heat treatment were then placed in a 65°C 
heated water bath for either 2, 5, 10, or 15min. Samples were cooled on ice and basal 
low serum medium consisting of 4.5g/mL glucose DMEM with 1% v/v FBS was then 
added to the mixture and transferred to cells. Negative controls consisting of wells free 
of BMP-2 included the low serum medium and low serum medium supplemented with 
the same concentrations of heparin or heparin derivatives used in the experimental wells. 
A schematic of the experimental timeline is shown in Figure 4.1.   
 
4.2.2.3 BMP-2 Bioactivity Assessment 
The C2C12 cells were cultured in the 96-well plate for an additional 72h, at 
which point, the wells were aspirated, washed twice with PBS with CaCl2/MgCl2 and 
 




incubated with ddH2O for 20min at room temperature to lyse cells. The plates of cells 
were frozen, thawed, and mechanically scraped to retrieve cell lysate. Cell lysates were 
sonicated for 20min and the freeze-thaw-sonicate cycle was repeated once more. Cell 
lysates were spun down and the supernatants were collected into separate 
microcentrifuge tubes.  
Alkaline phosphate activity (ALP) was assayed using the p-nitrophenol 
phosphate substrate and a serial dilution of p-nitrophenol standards (0-1000µM). Briefly, 
50µL of samples and standards were aliquoted into each well of a clear 96-well plate 
and incubated with 50µL of 1.5M 2-amino-2-methyl-1-propanol (Sigma-Aldrich) 
solution at pH 10.25. Then 100µL of a freshly made 1:1 mixture of 20mM p-nitrophenol 
phosphate disodium salt hexahydrate and 10mM magnesium chloride was added to each 
well. The assay plate was sealed and incubated at 37°C until a colorimetric change was 
observed, at which point the assay time was recorded.  
In addition, the concentration of double stranded DNA was assayed by the 
PicoGreen (Invitrogen) assay. Briefly, λ DNA standards (0-4µg/mL) were prepared in 
RNase/DNase free H2O. 1x TE buffer was prepared in RNase/DNase free H2O and the 
PicoGreen dsDNA reagent was diluted 200-fold in 1x TE buffer. In each well of an 
opaque 96-well plate, 43µL of sample or standard was incubated with 107µL of 1x TE 
buffer, and 150µL of PicoGreen solution. All samples were assayed in duplicates. The 
ALP activity (nmol of p-nitrophenol/mL/min) of each sample was normalized to its 
dsDNA concentration (µg/mL) and then normalized to the activity level of the positive 
control of untreated BMP-2 administered to C2C12.     
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4.2.3 Differential Scanning Fluorimetry (DSF) of Model Protein and Heparin 
Species 
Experiments were performed using a StepOne Plus Real Time polymerase chain 
reaction System (Applied Biosystems). A melting protocol was designed with a 2min 
pre-warming step at 31°C and a gradient up to 81°C in steps of 0.5°C as previously 
reported [201, 299]. Data were collected using the TAMRA dye setting (λex 560nm/λem 
582nm), with quencher and reporter dye set to “none”. Fluorescence data and derivative 
data were analyzed by the Protein Thermal Shift software (Applied Biosystems).  
DSF plates were prepared such that 10µL volumes were placed within each well, 
containing 20µM lysine-rich histone (Sigma-Aldrich), 10µM heparin species, 5X of 
Sypro Orange (Invitrogen) and PBS without CaCl2/MgCl2.  Prior to placement in wells, 
mixtures were prepared in low-binding polypropylene microcentrifuge tubes with 
enough volume for quadruplicates. Stock solutions of histone and heparins were made 
separately in PBS. The fluorescent dye Sypro Orange 5,000x (Invitrogen) was diluted 
100x in ddH2O, vortexed until mixed, kept protected from light, and used within 1h. For 
each mixture, histone was mixed with heparin and PBS and incubated at room 
temperature for 10min. Finally, Sypro Orange was added to the solution and carefully 
mixed. Controls consisted of each component (PBS buffer, histone-only, and heparin 
species only) with 5X Sypro Orange. Aliquots of 10µL of each mixture were placed into 
each well of a Fast Optical 96-well Reaction Plate (Applied Biosystems) and sealed with 
Optical Adhesive Film (Applied Biosystems). Plates were briefly centrifuged for 1min at 
1000 RPM to remove bubbles and draw all solutions to the bottoms of the wells. Plates 
were then placed into the PCR instrument for the denaturation experiment with the 
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assigned melting protocol. Data is presented as representative curves from experiments 
performed in quadruplicate.   
4.2.4 Statistical Analysis 
DMMB, Mn, PI, and BMP-2 bioactivity data are presented as mean ± standard 
deviation. One- and two-way analysis of variance (ANOVA) were used to identify 
significant differences or interactions. Tukey’s post hoc multiple comparison test with a 
significance value set at p<0.05 indicated significant differences between individual 
samples. Statistical analysis was performed with Minitab (v15.1).    
 
4.3 Results 
4.3.1 Heparin Modification and Characterization 
The DMMB assay was used to assess overall sulfation levels of heparins 
desulfated by the various protocols. Increasing concentrations of modified heparins were 
plotted against the absorbance of DMMB. In comparison to the native heparin molecule, 
Hep-N, Hep-N,-6O, and Hep- were approximately 82.2%, 39.2%, and 0.7% as sulfated, 
indicating a stepwise decrease in sulfation due to the desulfation protocols (Figure 4.2b). 
The molecular weight of the heparin species were resolved against a range of 
PEO standards on a GPC running on an aqueous method. The molecular weight for Hep- 
was significantly smaller than Hep and Hep-N (Table 4.1). In addition, the polydispersity 






 Proton NMR showed specific chemical shifts upon desulfation protocols. 
Hydrogen atoms on heparin (Figure 4.3) exhibited shifts upon N-desulfation (a), 2-O 
desulfation (b, c), and 6-O desulfation (d). There was some evidence of 2-O desulfation 
upon the N-desulfation protocol, and more complete 2-O desulfation upon the 6-O, N-
 
Figure 4.2. Common sulfation positions on heparin disaccharide and effect of 
desulfation protocols on native heparin. (a) Boxed regions represent positions that are 
sensitive to the desulfation protocols. (b) Overall sulfation levels of modified heparins 
compared to native heparin as measured by absorbance of DMMB. * indicates that 
normalized absorbance of sample was significantly different than all other derivatives, 
p≤0.05, n=3, mean ± s.d. 
 Mn ± s.d. PI ± s.d. 
Hep 25,200±5,500 1.2±0.05 
Hep-N 29,400±60 1.3±0.00 
Hep-N,-6O 22,200±260 1.5±0.03 
Hep- 17,800±240^# 1.5±0.01 
Table 4.1 Number average molecular weight (Mn) and polydispersity (PI) of heparin 
species compared to PEG standards. ^ indicates significant difference from Hep, # 
indicates significant difference from Hep-N . p≤0.05, n=3, mean ± s.d. 
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desulfation protocol. Complete desulfation of heparin exhibits the N-, 2-O, and 6-O 




Figure 4.3. 1H NMR spectra for desulfated heparin species. Letters correspond to the 
position of the hydrogen depicted on the chemical structure. The chemical shifts after 
N-desulfation suggests changes near the amino group (a) and minor 2-O desulfation 
(b). Hep-N,-6O show further 2-O desulfation (c) and shifts due to 6-O desulfation (d). 
Spectra of Hep- appears similar to Hep-N,-6O, but with more defined peaks, as well as a 
more prominent signal near 4.85ppm, indicating the presence of glucuronic acid.  
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4.3.2 Cell-Based BMP-2 Bioactivity Assay 
BMP-2 bioactivity was assessed after heat treatment at 65°C by administering 
treated samples to C2C12 cells and evaluating for ALP activity after a 3 day incubation 
period. Each sample was normalized to an ALP activity level induced by untreated 
BMP-2 in order to minimize differences across plates. Negative controls of low serum 
(1% FBS) basal medium and medium supplemented with heparin species did not induce 
significant ALP activity in C2C12 cells over 3 days (Figure 4.4a). When BMP-2 was 
pre-treated with heat, a significant drop in bioactivity was observed with as short as a 
2min heating period compared to untreated (“0min”) BMP-2 (Figure 4.4b). When BMP-
2 was complexed to 10 molar excess heparin, no drop in bioactivity was detected until 
the complex was pre-treated with 10min of heat. Also by 10min of heat treatment, the 
10:1 complex showed less BMP-2 bioactivity than the 100:1 complex, a feature that was 
repeated at 15min of heat treatment. Unlike the BMP-2-alone and 10:1 complex, the 
100:1 complex did not show a significant decrease in bioactivity over heat treatment 
times. In addition, the 100:1 complex exhibited significantly higher ALP activity than 
BMP-2-alone over all heat treatment times. With 15min of heat treatment, the 100:1 
complex retained approximately 70% of the ALP activity induced by untreated BMP-2 
(Figure 4.4b). 
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 Initial differences in ALP activity were observed when BMP-2 was co-delivered 
with chemically desulfated heparin species. Co-delivery with Hep-N or Hep-N,-6O showed 
significantly lower ALP activity than BMP-2-alone (Figure 4.5). In addition, Hep-N 
showed lower ALP activity than Hep co-delivery at 0min. Upon heat treatment for both 
times, BMP-2 was significantly less bioactive than untreated BMP-2. While BMP-2 
complexed to Hep showed no significant difference in bioactivity over heating time, 
Hep-N co-delivery exhibited an initial drop in bioactivity after 2min of heating yet 
retained approximately 35% of the ALP activity of the untreated BMP-2 positive control 
after 15min of heating. Hep-N,-6O co-delivery exhibited a lower ALP activity after 15min 
of heating compared to its unheated control, and was significantly lower than the ALP 
activity induced by Hep co-delivery. When Hep-, the modification that carries the least 
amount of sulfation, was co-delivered with BMP-2, it had a similar level of bioactivity 
Figure 4.4. Normalized BMP-2 bioactivity levels after pre-treating BMP-2 with heat 
for various times prior to administration to C2C12 cells. (a) ALP activity for BMP-
free control cultures showing no significant differences. (b) BMP-2 saw a significant 
drop in bioactivity after 2min of heating, while 10:1 heparin:BMP did not exhibit a 
significant drop until 10min of heating. There were no significant differences in 
bioactivity of 100:1 heparin:BMP groups over treatment time. All BMP activity values 
were normalized to an untreated BMP-2 control. * indicates significantly different than 
other samples within same treatment time, † lower than 100:1 within same treatment 
time, ‡ different from 0min for same sample, § different from 10min for same sample, 
¶ different from 15min for same sample. p<0.05, n=4, mean ± s.d.    
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as BMP-2 at 0min (~71% of untreated BMP-2 bioactivity), but had only approximately 
17% of bioactivity after 15min of heating. With 15min of heating, BMP-bioactivity is 
significantly higher when co-delivered with Hep, Hep-N, and Hep-N,-6O when compared 
to BMP-2-alone.  
 
4.3.3 DSF of Model Protein and Heparin Species  
Differential scanning fluorimetry (DSF) is a method that uses a fluorescent dye 
that can bind to the core hydrophobic residues of denatured proteins [300]. Upon 
increasing temperatures, many proteins exhibit an unfolding transition where the 
hydrophobic dye can bind to core residues, producing an increasing fluorescence signal 
with increasing temperature. Upon reaching a maximum fluorescence, the fluorescent 
signal gradually decreases as proteins aggregate at higher temperatures. Fluorescence 
 
Figure 4.5. Normalized BMP-2 bioactivity over heat treatment time and co-delivery 
with modified heparins. With 15min of heat treatment, BMP-2 co-delivered with Hep, 
Hep-N, or Hep-N,-6O showed higher bioactivity than BMP-2 alone. All BMP activity 
values were normalized to an untreated BMP-2 control. * indicates significantly 
different than Hep within the same treatment time, † different from Hep-N within the 
same treatment time, ‡ different from Hep-N,-6O within the same treatment time, § 
different from 0min of same sample type, ¶ different from 15min of same sample 
type. p<0.05, n=4, mean ± s.d.    
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spectra can be analyzed by performing the first derivative on data to find the point where 
the concentration of unfolded protein is in equilibrium with folded protein, also known 
as the melting temperature (Tm) [300]. 
Representative fluorescence curve profiles and selected first derivative curves are 
depicted in Figure 4.6. Heparin and its desulfated derivatives show no change in 
fluorescence over the tested temperature range (Figure 4.6a, inset), indicating that the 
glycosaminoglycans do not interact directly with the Sypro Orange dye. Histone alone 
did not show a clear melting curve, but addition of specific heparins induced a melting 
profile. Incubation with 10µM heparin induced a sigmoidal fluorescence profile in 
histone (Figure 4.6a) and a corresponding first derivative melting curve (Figure 4.6b), 
with an approximate Tm of 39.7±1.1°C. Hep-N also induced a sigmoidal fluorescence 
profile in histone and melting curve (Figure 4.6a, b), with an average Tm of 45.4±0.8°C. 
Addition of Hep-N,-6O or Hep- to histone did not produce sharp melting curves (Fig. 3.6a) 




An established BMP-2 bioactivity assay was used to determine the effect of 
heparin species of varying sulfation on maintaining BMP-2 bioactivity during thermal 
stress. Heparin with reduced anti-coagulation activity would be amenable for use in in 
vivo delivery systems and these materials have been developed through selective 
desulfation [290, 297, 301]. The goal of this study was to determine if sulfation level of 
heparin correlated to the level of BMP-2 bioactivity after heat treatment and evaluate the 
interaction between desulfated heparin species and proteins.  
In characterizing the desulfated heparin species produced in this study, both 
overall sulfation level as well as molecular weight changes after chemical treatment 
were evaluated. For the same mass concentration of heparin species, the DMMB assay 
showed that overall sulfation level decreased as heparin was N-desulfated, 6-O,N-
desulfated, and completely desulfated (Figure 4.2). Heparin was relatively resistant to 
!
Figure 4.6. Representative fluorescence spectra of histone and heparin derivatives with 
DSF. (a) Histone fluorescence when incubated with heparin species. Hep and Hep-N 
induce a conformational change in histone to produce a clear DSF signal. Inset figure 
shows fluorescence from negative controls of heparin materials alone. (b) First 
derivative of fluorescence data for histone incubated in Hep and Hep-N. The maximum 
of each curve represents the Tm. All samples were repeated in quadruplicate.    
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chain scission when treated with acidic methanol for complete desulfation, although the 
product, Hep-, had a significantly lower molecular weight than Hep and Hep-N (Table 
4.1). The N-desulfation of heparin was achieved by removing the more reactive N-
sulfate groups with a solvent that does not induce hydrolysis at the glycosidic linkages 
[290]. Proton NMR showed that chemical desulfation produced spectra shifts in 
expected locations and suggested that the chemical processes were specific. Evidence of 
iduronic to glucuronic epimerization was noted for Hep- (Figure 4.3), suggesting that 
desulfation processes may affect heparin conformation. 
In these studies, a non-glycosylated version of BMP-2 was used to probe the 
effect of thermal stress. The benefit of using non-glycosylated BMP-2 in these studies 
was the suitability in understanding how the protein backbone may be affected by 
external factors and interactions. Glycosylated BMP-2 has glycans attached to the 
protein backbone that can affect protein folding and response to thermal stress. The form 
of BMP-2 used in this study can more readily show the effects of thermal denaturation 
and provide valuable information on molecules that can stabilize its activity without the 
confounding effects of glycans.   
The results of these experiments show that non-glycosylated BMP-2 was 
sensitive to heat treatment (bioactivity was reduced to 34±0.03% after a 2min exposure 
to heat (Figure 4.4) and was protected by heparin co-delivery. The thermal stress of 
heating at 65°C appeared to cause non-reversible unfolding as bioactivity was not 
recovered after removal from heat. Native heparin at 100 molar excess was shown to 
maintain BMP-2 bioactivity at 68±0.09% over 15min of thermal stress compared to 
0.06% of BMP-2-alone. While a 10 molar excess of heparin  complexed to BMP-2 
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showed a decrease in bioactivity after 15min of heating, the bioactivity level was 
significantly higher than BMP-2-alone heated for the same amount of time. Complexes 
of 10:1 heparin:BMP-2 were a significant improvement in maintaining BMP-2 
bioactivity over free BMP-2 and an even higher excess of heparin seems to have 
additional effects on bioactivity when exposed to thermal stress. This heparin 
concentration dependence was similar to a past study with FGF-1, in which FGF-1 
experienced more thermal stability when incubated with increasing concentrations of 
heparin [302].  
While lower concentrations of heparin were able to change the secondary 
structure of a model protein (Supplementary figure A.2) an excess of heparin was 
chosen in order to ensure BMP-heparin interaction. These approximate molar ratio of 
heparin to protein have been used in a previous study investigating heparin with FGF-2 
and a delivery vehicle that showed modulated release with 100:1 heparin:growth factor 
concentrations [303, 304]. It has been estimated that 5-6 molecules of BMP-2 can be 
bound to each heparin chain, so there were heparin molecules that were not saturated 
with BMP in these studies [168]. It is possible that the excess of unoccupied heparin at 
100 molar excess may play an additional role in slowing denaturation of BMP-2. In 
studies of excipients used to stabilize proteins, increasing concentrations of the sugar 
trehalose was shown to increase the surface tension of the protein solution, which then 
required greater amounts of energy to change the solvation during denaturation [305].  
A 100 molar excess of desulfated heparin species was chosen for BMP-2 
bioactivity assays in order to maximize the potential interaction with the growth factor. 
All the desulfated species at 100 molar excess failed to be as effective as 100:1 
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Hep:BMP-2 at maintaining BMP-2 bioactivity when exposed to heat (Figure 4.5). While 
the overall sulfation of Hep-N was ~80% of native heparin (Figure 4.2b), the bioactivity 
after 2min of heating was ~30% of untreated BMP-2 compared to ~90% of Hep:BMP-2 
(Figure 4.5). Bioactivity of BMP-2 after 15min of heating was reduced with all the 
desulfated derivatives in comparison to 100:1 Hep:BMP-2 (Figure 4.5). Co-delivery 
with Hep-N and Hep-N,-6O resulted in similar BMP-2 bioactivity levels after 15min of 
heating, and were higher than the bioactivity of BMP-2 alone, suggesting that there may 
be protective effects due to residual sulfates on those heparin species. Co-delivery with 
Hep- exhibited a significantly lower BMP-2 bioactivity level than all other heparin 
derivatives after 15min of heating. The charged hydroxyl and carboxyl groups on Hep- 
were not sufficient in maintaining BMP-2 bioactivity at this level of thermal stress, 
suggesting that there is a sulfation-level dependence on maintaining BMP-2 bioactivity. 
It has been suggested previously that desulfated heparin species may not protect 
BMP-2 bioactivity [306]. However, in that study, samples were not heated and the co-
delivery of desulfated samples exhibited comparatively lower ALP activity values than 
presented here. It is possible that differences in desulfation methods and differences in 
the heparin concentrations used may have limited the amount of interaction between 
BMP-2 and the desulfated heparin derivatives in that previous study [306]. In both 
studies, the heparin backbone conformation may play a role in interactions between 
heparin and heparin-binding proteins. Heparin is a relatively flexible molecule, able to 
wrap itself around proteins during binding, driven primarily by the iduronic acid residue 
that can adopt several conformations [183, 198]. It is possible a change in heparin 
conformation occurred while undergoing desulfation procedures, as suggested with the 
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increased presence of glucuronic acid, a hexuronic acid with fewer conformations than 
L-iduronic acid, in 1H NMR results (Figure 4.3).  Any structural difference between 
Hep-, Hep-N and Hep-N,-6O may influence BMP-2 binding and bioactivity.  
In order to understand the interaction between desulfated heparin derivatives and 
proteins further, differential scanning fluorimetry (DSF) was used to gauge the evidence 
of heparin-protein complexation. DSF is a high-throughput, low volume method that 
utilizes a hydrophobic dye to probe thermal unfolding of proteins in the presence of 
ligands [300]. This technique was used to demonstrate protein stability upon binding to 
glycosaminoglycans such as heparin and may be used to indicate interactions between 
proteins and glycosaminoglycans [201, 307]. The ability of a ligand to confer stability is 
reflected in a sigmoidal melting curve and a shift toward a higher melting temperature 
(Tm). While amenable for many proteins, some proteins may not produce an adequate 
signal, whether by not exhibiting a reversible two-state unfolding or exhibiting highly 
accessible hydrophobic residues that produce high initial background readings [300, 
308]. BMP-2 exhibits the latter limitation, causing high initial fluorescence that masked 
the melting regions. While a technique will need to be optimized in order to study the 
interactions between desulfated heparin species and BMP-2, DSF was used with a model 
protein to show how the heparin species may interact with BMP-2.  
DSF was used to measure the thermal stability of a positively-charged model 
protein, lysine-rich histone, in the presence of different heparin species. Lysine-rich 
histone, consisting primarily of f1 histone, is similar in size (~21.5kDa) to BMP-2 and 
has a net positive charge at physiological pH. No specific heparin-binding sequence on 
histone has been identified, but studies have shown that histone can have an altered 
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diffusion profile into heparin-containing hydrogels, suggesting some level of 
electrostatic interaction between the molecules [309]. Furthermore, the random coil 
structure of histone [310] was altered upon binding to Hep and Hep-N (Supplementary 
figure A.2). Histone itself has been shown to become more structurally defined upon 
binding to DNA [311], suggesting that it is amenable to studying interactions with acidic 
heparins.   
The denaturation profile of histone alone in DSF analysis shows no obvious 
transition (Figure 4.6a), which has been observed for certain proteins using the DSF 
technique [299]. However, in some cases, proteins without clear melting curves can 
obtain them following interaction with a ligand [299]. When histone was incubated with 
Hep, its melting profile became more defined, indicating that Hep was able to induce a 
structural change on histone that influences its unfolding behavior (Figure 4.6a). The 
sigmoidal melting profile shown in the overall fluorescence (Figure 4.6a) was repeated 
when histone was incubated with Hep-N. However, Hep-N,-6O and Hep- fail to induce a 
significant transition in fluorescence with increased temperature. While the absolute 
values of fluorescence in the melting curves are informative, the shape of the curves is 
especially telling about the interactions between the heparins and histone. Hep and Hep-
N contain more sulfate groups, hence negative charge, for histone to interact with to 
induce an initial structural change in histone that can be traced through unfolding by 
DSF. On the other hand, histone incubation with Hep-N,-6O had a much lower signal and 
broader profile. Addition of Hep- produced melting curves more similar to histone alone. 
These results indicate that in terms of electrostatic interaction, the amount of sulfation 
on heparin determines the extent of interaction. When sulfation drops to below 40% of 
! 86 
native heparin, as in the case of Hep-N,-6O and Hep- (Figure 4.2b) the interaction between 
the heparin derivative and histone become significantly weakened (Figure 4.6a), leading 
to a lack of sufficient structural change to induce a clear melting transition. This 
observation is a different perspective on the value of incubating Hep-N,-6O with BMP-2 
during thermal stress. It appeared that Hep-N,-6O was effective in protecting BMP-2 from 
thermal stress up to 15min of heat exposure (Figure 4.5), which suggest that there may 
be sulfation pattern sequences that BMP-2 recognize.  
BMPs are powerful morphogens that can affect many cellular processes and are 
of interest in regenerative medicine. The ability to improve the half-life of BMP-2 in 
solution and in delivery systems will enable the delivery of lower doses of BMP-2, 
resulting in more effective and cost efficient therapeutics. Use of heparin-derived 
materials with decreased anti-coagulant activity will allow the design of scaffolds that 
feature high affinity for BMP-2 as well as maintenance of BMP-2 bioactivity. The 
results of this study can also allow the selection of materials to study the effects of 
heparin-derivative:BMP-2 complexes either in soluble form, from coacervates, or from 
scaffolds. Furthermore, fundamental studies to determine how the interaction between 
heparin derivatives and a positively-charged protein can be disrupted or how these 
complexes interact with other glycosaminoglycan-based biomaterials can inform the 
success of these complexes (Supplementary figures A.3.2, A.3.3). Overall, by 
understanding growth factor interactions with sulfated GAGs, these fundamental results 





 These studies build upon what is currently known about BMP-2 interactions with 
heparin and seek to establish a role of heparin sulfation level in maintenance of BMP-2 
bioactivity. Native heparin maintained a significant portion of BMP-2 bioactivity when 
exposed to thermal stress and at particularly long times, the effect appeared to be 
heparin concentration dependent. While desulfated heparin derivatives were not as 
effective as native heparin in maintaining BMP-2 bioactivity, Hep-N and Hep-N,-6O were 
beneficial when administered prior to exposure to thermal stress at particularly long 
times compared to BMP-2-alone. This indicates that sulfation has some effect in 
maintaining BMP-2 bioactivity, but the backbone structure of the heparin derivatives 
may also determine the affinity and extent of protective effects they can confer to BMP-
2 in solution. Hep and Hep-N were found to induce a conformational change within a 
model positively-charged protein, suggesting that these heparin species can directly 
interact with the protein, forming a complex. Taken together, Hep-N has shown the best 
qualities in terms of retaining high overall sulfation, maintaining BMP-2 bioactivity 
during heat treatment, and exhibiting evidence of direct interaction with a model protein 
compared to the other desulfated species. Future development of heparin-derived 
materials can take advantage of these features in order to most effectively deliver growth 
factors. The ability of desulfated heparin species to exhibit low anti-coagulant activity, 
improve the half-life of BMP-2 in solution and in delivery systems, and exhibit affinity 
to BMP-2 will enable the delivery of lower doses of BMP-2, resulting in more effective 




CATHEPSIN ACTIVITY INCREASES IN THE INSERTION REGION OF RAT 
SUPRASPINATUS TENDON WITH OVERUSE 
 
5.1 Introduction 
The etiology of supraspinatus tendinopathy is multifactorial, with impingement 
by the coracoacromial arch and overuse being commonly cited factors[312]. In regards 
to animal models pertinent to the study of this pathology, the rat has been shown to have 
similar shoulder anatomy to humans, with a coracoacromial process that the 
supraspinatus tendon slides beneath[112]. Tendon overuse in this rat model has shown 
altered biomechanical properties[313] and decreased gene expression of type I and III 
collagens.[314] Changes in tendon architecture were also observed with this overuse 
protocol[313], but mechanisms for the tissue degeneration have not been defined.   
Type I collagen is the main extracellular matrix constituent of tendon that 
imparts the tensile strength necessary for tendon function and can exhibit disrupted 
organization upon injury[315]. Furthermore, supraspinatus tendons have shown 
decreased collagen content or expression as a result of degeneration or failed 
healing[100, 124]. The importance of collagen catabolism as a part of pathology 
progression in tendinopathy has resulted in a focus on the family of matrix 
metalloproteinases (MMPs). Previous studies examining the healing of tendon after 
tendon rupture have found increases in expression and activity of MMP-1[316] and 
MMP-13,[317] but a range of proteases likely take part in tendon degeneration.  
The contributions of cysteine cathepsins, a family of lysosomal and secreted 
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proteases, are increasingly recognized in tissue maintenance and a variety of 
degenerative tissue diseases. They have been identified as the most potent mammalian 
collagenases capable of cleaving types I and II collagens both intrahelically and at the 
telopeptide regions, whereas other collagenases only cleave at one or the other[318]. 
Cathepsin K, associated with bone remodeling, has been implicated in collagen 
proteolysis in osteoarthritis[40], while cathepsin L, potent in cleaving at collagen 
telopeptide regions, has been found in myopathies[319]. Additionally, cathepsins can 
play important roles in activating other proteases such as MMPs[320] and the serine 
proteases urokinase-type plasminogen activator[321]. Sustained expression of these 
proteases has been linked with chronic tissue degeneration and disease progression[322]. 
Since cathepsins have a vital role in initializing and significantly contributing to 
proteolytic cascades, their involvement in tendon degeneration may shed light on the 
mechanisms of chronic tendon diseases.   
With this in mind, a detailed study to examine the role of cathepsins in a rat 
model of tendon overuse was designed. After up to 8 weeks of decline running on a 
treadmill, supraspinatus tendons of Dahl Salt Resistant rats were analyzed for 
differences between the region closest to the osseotendinous junction (the insertion 
region) and the region encased in muscle (the midsubstance region). Tissue damage was 
evaluated histologically and contralateral tendons underwent analysis via gelatin 
zymography. Multiplex cathepsin zymography is a sensitive electrophoretic technique 
that separates proteases and correlates the gelatin substrate digestion with proteolytic 
activity,[323] and can be more sensitive than Western blotting[324]. In this study, we 
hypothesized that the overuse protocol would primarily cause tissue damage at the 
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insertion region (due to possible impingement from the overlying acromion) and that 
there would be a concomitant increase in cathepsin activity in the overused tendon. 
 
5.2 Materials and Methods 
5.2.1 Rat Model 
Twenty-four male Dahl Salt Resistant rats (330±20g initial weight, 12-13 weeks initial 
age, Harlan Labs) were used in this study, as approved by Georgia Institute of 
Technology’s Institutional Animal Care and Use Committee.  Twelve rats were 
acclimated to the running regime for 2 weeks to run at a final speed of 17m/min at a 10° 
decline for 1 hour/day for 5 days/week, as described previously[313]. In the 
experimental group, rats were subjected to overuse exercise for 4 or 8 weeks 
(n=6/group). Age-matched rats that were allowed cage activity served as controls 
(n=6/timepoint). At each endpoint, the supraspinatus muscle was detached from the 
scapula and the humerus was bisected by bone rongeurs. The bone-tendon-muscle units 
were wrapped individually in saline-soaked gauze and frozen until further processing.   
5.2.2 Histological Staining and Scoring  
For histological evaluation, tendons were thawed and peritendon tissue and the 
majority of muscle were removed. Tendons were sharply dissected from their bony 
attachment. To prepare samples for cryosectioning, tendons were embedded in a 40:60 
solution of 20% sucrose:optimum cutting temperature (OCT) compound (Sakura 
Finetek) solution, placed under vacuum for 10h to increase penetration of embedding 
medium, and frozen in isopentane chilled by liquid nitrogen.  
Therafter, tendons were sectioned with a cryostat (Thermo Scientific CryoStar 
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NX70) into 10µm sections, longitudinal to the tendon. Slides stained with hemaxotylin 
(Sigma-Aldrich) and eosin (EMD Chemicals) (H&E) were imaged with a Nikon Eclipse 
80i. Slides stained with picrosirius red (Sigma-Aldrich) were imaged with an Olympus 
BX51 polarized light microscope mounted with an Olympus Camedia C-5060 digital 
camera. Histological grading of H&E stained sections was carried out using a semi-
quantitative scale, similar to the Bonar and Movin scales.[325, 326] Categories for 
histological scoring included regional variations in cellularity, cell shape, collagen fiber 
organization, and vascularity (Table 5.1). A 4-point scoring system was used, where 0 
indicated normal appearance and 3 a markedly abnormal appearance. Four graders (JL, 
MG, TER, TM), blinded to the sample types, scored 4 images from each tendon (n=3 
tendons/group/timepoint). Within each timepoint, the categorical scores of the control 
and experimental groups were compared. 
5.2.3 Multiplex Cathepsin Zymography  
For cathepsin zymography, tendons were isolated from muscle and bone. The 
tendons were systematically divided into the insertion and midsubstance regions by 
transecting the tendon at 17% of the total length from the insertion end. This proportion 
consistently excluded the region encased in muscle from the insertion region and 
provided enough protein for subsequent assays. Subsequently, samples were diced and 
homogenized in PlusOne grinding kits (GE Healthcare) in lysis buffer (20 nM Tris–HCl 
at pH 7.5, 5 mM ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid 
(Sigma-Aldrich), 150 mM NaCl (BDH), 20 mM β-glycerolphosphate (Alfa Aesar), 10 
mM NaF (Sigma-Aldrich), 1 mM sodium orthovanadate (Sigma-Aldrich), 1% Triton X-
100 (EMD Chemicals), 0.1% Tween-20 (Fisher Scientific)) with freshly added 0.1 mM 
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leupeptin (Affymetrix). Samples were subject to zymography as described 
previously[323]. Supernatants were cleared by centrifugation and collected. Protein 
quantification of supernatants was performed with a micro BCA kit (Pierce). Cathepsin 
zymography was performed on tissue lysates. Briefly, non-reducing loading buffer (5X 
– 0.05% bromophenol blue (Fisher Scientific), 10% sodium dodecyl sulfate (SDS, 
Amresco), 1.5M Tris (Fisher Scientific), 50% glycerol (EMD Chemicals)) was added to 
12µg of protein prior to loading samples into gel. Control and experimental samples 
from the same timepoint were run on the same gel (n=4/group), with 8.3ng cathepsin V 
(Enzo Chemicals) as a positive control. Samples were loaded into 12.5% SDS-
polyacrylamide (Protogel) gels containing 0.2% gelatin (Sigma-Aldrich) and resolved at 
110V at 4°C. Enzymes within gels were renatured in 65mM Tris buffer pH 7.4 with 
20% glycerol for 3 washes, 10min each. Gels were then incubated in pH 4 activity 
buffer (acetate buffer, 1mM ethylenediamine tetraacetic acid (Fisher Scientific), freshly 
added 2 mM dithiothreitol (Sigma-Aldrich)) for 17h at 37°C. Thereafter, gels were 
rinsed and stained with Coomassie Blue (Sigma-Aldrich) and imaged with an 
ImageQuant LAS 4000 (GE Healthcare). To limit variability, samples from the same 
timepoint were processed in parallel and gels were imaged simultaneously. 
Densitometry analysis was performed on images using ImageJ (NIH) to quantify the 
cleared bands that represent proteolytic activity. Values were normalized to the 






5.2.4 Immunofluorescence Staining  
For immunofluorescence, slides were fixed in acetone (BDH), blocked with 2% 
normal goat serum (Vector Labs) for 1h and incubated with 1:100 dilution rabbit anti-rat 
cathepsin K (Santa Cruz Biotechnology) or L (Abcam) primary antibody overnight at 
4°C in a humidified chamber. Goat anti-rabbit secondary antibody (Invitrogen) at 1:200 
dilution was applied and sections were counterstained with 4’,6-diamidino-2-
phenylindole dihydrochloride (DAPI, Anaspec) and imaged with a Nikon Eclipse 
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capillaries (1 vessel 
per field of view) 
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view) 
Greater than 2 
clusters of 
capillaries per field 
of view 
Table 5.1 Semi-quantitative scoring matrix for H&E sections. 
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5.2.5 Statistical Analysis 
Categorical scores from histological evaluation were compared between the 
control and running groups by the non-parametric Mann-Whitney test. Data from 
cathepsin zymography were Box-Cox transformed and analyzed by t-tests on a per 
zymogram basis. All statistical analyses were evaluated at a statistical significance level 
of p<0.05. Statistical analysis was performed with Minitab software. 
 
5.3 Results 
5.3.1 Histological Imaging and Scoring  
H&E stained histological sections revealed that tissue-level changes were more 
prominent in the insertion regions of the tendons compared to the midsubstance regions. 
The 4-week control tendon (Figure 5.1a) showed tightly packed fibers and aligned cells 
at the insertion region. The 4-week overuse insertion region (Figure 5.1b) showed minor 
collagen disorganization, as evidenced by the appearance of demarcated fibers with less 
dense staining between them, but collagen fiber bundles remained largely intact. The 8-
week control insertion region displayed mostly intact collagen bundles with sparse and 
aligned tenocytes (Figure 5.1c). By 8 weeks of overuse, collagen fiber thinning and 
separation from larger bundles was more obvious in the tendon insertion region (Figure 
5.1d) compared to the age-matched control (Figure 5.1c). In contrast to the changes 
observed at the insertion regions, the midsubstance regions, where tendon is encased in 
muscle, exhibited similar morphology across time and condition: tightly packed collagen 
fibers with elongated tenocytes oriented along the axis of the tendon (Figure 5.1e-h). 
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H&E-stained control and experimental samples evaluated within each timepoint 
by the semi-quantitative scoring system (Table 5.1) showed significant differences only 
at the insertion region. For the 4-week group, although the medians were the same 
between overuse and control group, the distribution in scores for cell shape at the 
insertion region was significantly different, with more instances of cell roundness (as 
indicated by nuclei shape) noted in the overuse group (Table 5.2). More regional 
variation in cellularity was observed in the 4-week control insertion region compared to 
the overuse group, suggesting that a portion of cells in control tendons were not as 
uniformly distributed.  For the 8-week group, both cell shape and fiber organization 
scores were significantly different (Table 5.2). The insertion region of the 8-week 
overuse group showed more cells with increased roundness and size (Figure 5.1) than 
 
 
Figure 5.1 Changes to supraspinatus tendon structure obvious by 8 weeks of overuse. 
The insertion region of the 4-week control (a) and 8-week control (c) tendons are 
contrasted with insertion region of the 4-week overuse (b) and 8-week overuse (d) 
tendons. The tissue structures of the midsubstance regions (e-h) were comparable 
across all groups. n=2, scale bar=100µm.  
!
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the control group. Additionally, in regards to collagen fiber organization, the insertion 
region of the 8-week overuse group showed more instances of fiber separation than the 
control group. Vascularity, denoted by clusters of capillaries, was rarely noted by the 
observers in the tendon sections and assigned scores did not show any significant 
difference between overuse and control groups.   
Picrosirius red stained sections imaged under circular polarized light exhibit 
yellow to red staining characteristic of large and organized collagen fibers (Figure 5.2). 
While the crimping pattern of the control insertion region was uniform and uninterrupted 
across the section (Figure 5.2a), the overuse insertion region showed less collagen 
packing and disturbed crimping (Figure 5.2b, boxes).   
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Table 5.2.  Summary of categorical histology scores of control and overused tendon at 
the insertion region. Data presented as median (range), * significantly different than 




5.3.2 Multiplex Cathepsin Zymography  
Incubation of the zymography gels in pH 4 activity buffer during the overnight 
assay period selects for murine cathepsin L over the other cathepsins, producing an 
active band between 25 – 35 kDa[323], and this activity was detected in all of the tendon 
samples as evidenced by the less dense bands in the gelatin gels (Figure 5.3a, d). 
Zymograms exhibited high molecular weight bands (50-75kDa) bands for some samples 
(Figure 5.3a), which were attributed to cathepsin K bound to extracellular matrix, as was 
seen in osteoclasts in previous studies[327]. Densitometric quantification of band 
intensities determined that by 4 weeks, the activity of cathepsins L and K were higher in 
the insertion region of the overuse group compared to the control group by 1.8-fold and 
4.2-fold, respectively (Figure 5.3b,c, n=3-4, p<0.05). Additionally, by 8 weeks, 
 
Figure 5.2 Picrosirius red-stained sections of tendons observed under circular 
polarized light microscopy.   8-week control (A) group contrast with the overuse 
group (B; boxes indicate disturbed crimp pattern). The midsubstance regions of the 
control (C) and overuse (D) groups were comparable. * indicates muscle, n=2, scale 
bar=50µm.    
!
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cathepsin L activity was 1.8-fold higher in the insertion region of the overuse group 
compared to age-matched controls (Figure 5.3e), although there was no longer a 
statistically significant increase for cathepsin K (Figure 5.3f). No significant differences 
were observed for cathepsin activity in the midsubstance regions between the overuse 
and control groups for either timepoint or cathepsins (Figure 5.3b, e).  
 
Figure 5.3 Cathepsin activity in supraspinatus tendon. Representative zymography gels 
(a, d) depict location of cathepsin K (higher molecular weight) and L (lower molecular 
weight). Cathepsin L activity in 4-week overuse (b) and 8-week overuse (e) tendons 
compared to age-matched controls. Cathepsin K activity in 4-week overuse (c) and 8-
week overuse (f) tendons compared to age-matched controls. n=3-4, * indicates 
significantly greater activity over control at the same time point (p<0.05).  
 
5.3.3 Immunofluorescence Staining  
Immunofluorescence staining was employed in order to confirm the presence of 
cathepsin L and K. Positive staining was confirmed with sections of rat spleen and 
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negative staining was conducted without the primary antibody (data not shown). 
Staining revealed that cathepsin staining was localized within or in close proximity to 
the cell. The tendon midsubstance regions showed similar positive levels of staining for 
overused and control tendons (data not shown), while there were more marked 
differences in staining at the insertion regions. For cathepsin L staining at the insertion 
regions, the 4- and 8-week controls showed similarly low levels of cathepsin staining 
(Figure 5.4a, b). The 4-week and 8-week overuse group (Figure 5.4e, f), showed more 
intense and uniformly distributed staining at the insertion region compared to their age-
matched controls (Figure 5.4a, b). Cathepsin K staining was slightly more variable in the 
4-week overuse group (Figure 5.4g), but overall showed more positive staining than 
seen in the controls (Figure 5.4c). The 8-week overuse group (Figure 5.4h) also 
exhibited more positive cathepsin K staining than in the controls (Figure 5.4d).  
 
Figure 5.4. Immunofluorescence staining of cathepsin localization in supraspinatus 
tendons. Cathepsin L staining (red) in the insertion regions of the 4-week (b) and 8-week 
(f) overused tendons compared to controls (a, e). Cathepsin K staining (red) in the 
insertion regions of the 4-week (d) and 8-week (h) overused tendons compared to their 




This study demonstrated the effects of overuse on cysteine cathepsin activity in 
supraspinatus tendon. A well-established rat overuse protocol[101, 313, 328] that 
features acromial impingement on the supraspinatus tendon was adapted for use with an 
inbred strain of rat to allow for the possibility to explore autologous cell therapy for 
overuse injuries in future studies. The inbred Dahl Salt Resistant rat strain was chosen 
for this study for their greater weight compared to other inbred strains. With the inbred 
rat strain, from histological analysis, we attain evident damage to the supraspinatus 
tendon after overuse. While significant damage occurred by 4 weeks of overuse in 
outbred strains[313], only minor histological damage was observed by 4 weeks in this 
study, possibly due to the lower weight of inbred versus outbred strain of rats. However, 
by 8 weeks of overuse, the insertion region of the supraspinatus tendon displayed 
obvious changes to the fiber organization and cell shape (Figure 5.1). Fiber separation 
from bundles and increased cell rounding were more evident by 8 weeks of overuse 
compared to the 4-week overuse group, indicating that increased time of overuse can 
cause accumulation of damage. Comparisons between the insertion regions of the 8-
week group showed differences in crimping pattern at the insertion (Figure 5.2). While 
the insertion region of the control tendon demonstrated tightly packed fibers with 
periodic and cohesive crimping, the insertion of the overuse tendon exhibited regions 
with flattened crimps and a loss of the periodicity of crimping. Reduction in tendon 
crimping can result from exercise-induced microtrauma[329], and may be a macroscopic 
representation of collagen disruption that can ultimately alter biomechanical 
properties[313]. By confirming the tendon tissue damage by H&E staining and polarized 
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light microscopy, we determined that this rat model was appropriate to study the 
molecular level changes in tendon overuse.  
The insertion region of the tendon is clinically relevant, as most damage and 
tears occur in this region, reflecting the complex mechanical forces imparted to this 
region[330]. Histological scoring displayed the differences between the overuse and 
control groups at the insertion region. Primary differences in scoring indicated 
observable changes to cell shape, which was detected by the 4-week timepoint, and fiber 
organization, which was observed by 8 weeks. Cell shape, reflected by the shape of 
nuclei, appeared to be rounder near the insertion of the overuse group, as noted 
previously[331]. The scoring results also further confirmed the disruption in collagen 
organization compared to controls at the insertion region by 8 weeks of overuse, 
potentially contributing to the decreased alignment of cells observed (Figure 5.1). The 
extent of tissue damage by 8 weeks period indicates a demonstrable overuse pathology. 
There was no observable neovascularization in the tissue sections, which may indicate 
that tendinopathy can occur without changes to vascularity as suggested previously[325]. 
While neovascularization has been observed in other studies, it may be a feature of a 
later stage of healing in response to tendon damage by other means such as tendon 
detachment[315].  
Our novel multiplex cathepsin zymography method has resulted in the first 
quantitative report that protease activity is upregulated specifically at the insertion 
region of overused tendon. Additionally, this is one of the few studies that has examined 
cathepsin expression in tendon. Previously, cathepsin D was detected only by 
immunohistochemistry within the granulation tissue of torn rotator cuff[332] and was 
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hypothesized to activate other chemical mediators. However, in this study, in the 
absence of granulation tissue, increased activity of cathepsin K and L were found within 
overused tendons (Figure 5.3). The specificity and sensitivity of gelatin zymography 
allows detection of femtomole quantities of cathepsin K[324] and detects only the active 
form of enzymes, which distinguishes it from antibody-based techniques and makes it 
ideal for use in tissue samples with low protein amounts, such as rat tendon.  
The increased expression of molecules such as nitric oxide synthase[328] or heat 
shock protein[101] early in tendon overuse can help discern molecular events in disease 
progression. In the same vein, in this study, detection of increased cathepsin K and L 
activity over controls by 4 weeks (Figure 5.3a, b, c) via zymography occurred before 
observable tissue damage. Other animal models have exhibited early cathepsin gene 
expression changes prior to the onset of orthopaedic diseases. In a transgenic Del1 
osteoarthritis mouse model, higher cathepsin K mRNA levels were observed 3 months 
before disease onset[333]. In UTU17 transgenic mice, which constitutively 
overexpresses the cathepsin K gene, early cathepsin K production was found in the 
synovial lining ahead of severe cartilage degeneration 5 months later[334]. These studies 
suggest that cathepsin K expression precedes many observable tissue changes that 
describe disease onset. It has been suggested that cathepsin K plays a major role in 
initiating fibrillar collagen degradation by exposing a greater number of sites for other 
collagenases to work and sustain the degradation[318]. In our study, cathepsin K 
exhibited a temporal response with overuse, with high activity at 4 weeks at the tendon 
insertion and minor activity by 8 weeks compared to age-matched controls (Figure 5.3f). 
While cathepsin K staining was positive by immunofluorescence for both timepoints, 
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antibodies generally do not distinguish between the inactive proform of the enzyme and 
the proteolytically active mature form of the enzyme.  
In contrast to early cathepsin expression that may start the cascade of tissue 
degradation, sustained cathepsin overexpression can cause accumulation of damage over 
time, which has been shown in an osteoarthritis mouse model with cathepsin K 
overexpression[335]. In the study presented here, at 8 weeks of overuse, cathepsin L 
activity remained higher in the overuse group than control tendons at the insertion, 
indicating that protein digestion remained elevated over time (Figure 5.3e). This 
sustained higher cathepsin L activity may suggest its importance in contributing to 
increased extracellular matrix degradation.   
Cathepsin K and L perform optimally at slightly acidic pH, which reinforces 
their roles in collagen degradation via local secretion or within the lysosomal 
compartments of tendon fibroblasts (Figure 5.4). These cathepsins can have 
interconnected functions with each other and with other proteases such as MMPs and 
serine proteases[320, 321], which are typically regulated by protease inhibitors. 
However, with certain diseases, protease activity can become misregulated and it may be 
beneficial to administer protease inhibitors to control tissue degeneration. Cathepsin 
activity in overused tendon may be a potential molecular target and has been explored in 
other orthopaedic diseases such as osteoporosis[336]. Administration of cathepsin 
inhibitors in osteoporosis studies have shown decreased collagen resorption markers and 
increased bone strength[337]. Since cysteine cathepsin inhibitors have been shown to be 
promising in other diseases, delivery of cathepsin inhibitors may be a promising method 
to slow the progression of collagen destruction in degenerative tendon disorders. One 
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cysteine cathepsin of interest is cystatin C, an extracellular cathepsin inhibitor that binds 
to cathepsins [134]. It is positively-charged at physiological pH, making it a potential 
therapeutic to deliver through affinity biomaterials (Supplementary figure A.4).   
The results shown here represent a fundamental study on the role of a new class 
of enzymes within overused tendon, but questions still remain. Additional studies will 
need to be conducted to establish the specific roles and timecourse of cathepsins in the 
progression of clinical tendinopathy. This involves evaluating the timecourse of 
cathepsin K expression and correlating degree of matrix turnover with cathepsin activity 
during overuse. And in the same vein, in order to evaluate the potency of cathepsins in 
tendon degeneration, it will be important to study local and selective cathepsin inhibition 
within overused tendon.  
 
5.5 Conclusions 
Cathepsin activity is a novel potential mechanism for tendon degeneration that 
has not been shown previously in tendon overuse. Differences in tissue structure and 
quantitative cathepsin activity were greatest at the insertion region, where most tendon 
ruptures occur[330]. Understanding the role of cathepsins in tendon overuse may help 
develop treatment plans to prevent tendon rupture by the local application of cathepsin 
inhibitors. While it is recognized that tendinopathy represents a range of 
pathologies[338], in this study, cathepsin upregulation relatively early and in specific 
areas of the tendon suggest that these proteases may play a very important role in the 
cascades of events that occur prior to tendon failure and make them an exciting potential 
target for future molecular therapies. 
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CHAPTER 6 
CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 Summary 
 Over 200,000 Americans per year require shoulder surgery to repair the rotator 
cuff, with the volume of repairs likely increasing as the current population ages [3]. 
Surgical repair can alleviate symptomatic shoulder dysfunction, but the rate of revision 
surgeries can be as high as 57% and do not address the underlying pathophysiology [4]. 
A physiologically relevant animal model to understand tendon degeneration and tissue 
engineering strategies to improve the current outcomes of tendon reattachment repairs 
represent a multi-faceted approach to treating rotator cuff tendinopathy. 
Since poor tendon-bone integration is a leading cause for revision surgery, the 
introduction of reparative cells or bioactive factors can help accelerate early stages of 
healing and stabilize the tendon-bone interface [5-7]. Mesenchymal stem cells (MSCs) 
are multipotent progenitor cells that are capable of differentiating into bone, cartilage, 
and fibrous tissues [13]. While direct injection of MSCs into tendon defects has had 
limited success, use of biomaterial carriers and preculture of MSCs are alternatives to 
improve retention and tissue repair [12, 14, 151]. In vitro conditioning of MSCs by 
coculturing MSCs within a 3D hydrogel with a differentiated cell type may direct MSCs 
toward a desired phenotype that can stabilize the tendon-bone interface. Furthermore, 
the design of the hydrogel can affect the cell microenvironment, determine the 
presentation of soluble signals, and ultimately determine the efficacy of preculturing 
! 106 
MSCs within a 3D scaffold. Due to their versatile functions, glycosaminoglycans 
(GAGs) have garnered interest for use as biomaterials in tissue engineering applications. 
Heparin is a highly-sulfated GAG that has been implicated in biological 
processes such as tissue morphogenesis, regulation of growth factor availability, and 
protection of growth factors from denaturation [30, 205, 217]. Translation of heparin 
biomaterials in vivo, however, is hampered by its anti-coagulant property [289]. 
Selective desulfation of heparin has been shown to significantly decrease its 
anticoagulant activity [290] and may allow the retention of its other biological roles for 
tissue engineering applications.  
There were 2 overall goals of this dissertation: 1) evaluate heparin and desulfated 
heparin derivatives as biomaterials for MSC encapsulation and growth factor carriers, 
and 2) characterize a rotator cuff overuse animal model for histological and enzymatic 
changes. To achieve this, heparin was chemically modified to allow covalent attachment 
within a synthetic hydrogel network and subsequently used in encapsulating MSCs for 
coculture with osteoblasts. Upon finding out that sulfation level can affect overall 
coculture results, soluble desulfated heparin derivatives were examined for their BMP-2 
protection capacity and protein interactions. Finally, to understand the cellular and 
molecular changes that occur in overused tendon prior to tendon rupture, the 
supraspinatus tendons of an inbred strain of rat were evaluated after 4 and 8 weeks of 
downhill treadmill running. 
In Chapter 3, synthetic poly(ethylene glycol)-based hydrogels with varying 
concentrations of heparin methacrylamide were designed to determine if immobilized 
heparin influenced the levels of osteogenic markers of encapsulated MSCs when 
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cocultured with monolayers of osteoblasts. MSCs encapsulated with 10% wt. heparin-
containing hydrogels exhibited significant increases in alkaline phosphatase (ALP) 
activity and calcium accumulation by 21 days when cocultured with osteoblasts 
compared to cocultures with MSCs. Five times more MSCs were encapsulated in 
hydrogels than osteoblasts in monolayers, suggesting that the hydrogel format can be 
amenable for pre-treating a large population of MSCs. However, with hydrogels 
containing the highest amount of heparin, mineralization was observed to occur 
primarily on the edges of the hydrogels, suggesting that MSC response to coculture was 
not uniform throughout the depth of the hydrogels. Subsequent model protein pull-in 
studies showed that high amounts of immobilized heparin can affect the distribution of 
soluble positively-charged proteins within bulk hydrogels. 
 In order to overcome the diffusional barriers seen in Chapter 3 and to ablate the 
anti-coagulant activity of native heparin, desulfated heparin derivatives were synthesized 
and evaluated by their protein interactions. In Chapter 4, selective desulfation of heparin 
was performed according to established protocols to produce N-desulfated heparin (Hep-
N), 6-O, N-desulfated heparin (Hep-N,-6O) and entirely desulfated heparin (Hep-) [290, 
296, 297, 301]. Non-glycosylated BMP-2, a heparin-binding growth factor, was heat 
treated with or without heparin species prior to administration to the C2C12 cell line to 
determine growth factor bioactivity. Native heparin was the most effective in protecting 
BMP-2 bioactivity against thermal denaturation, as evidenced by significantly higher 
alkaline phosphatase (ALP) activity across different heat treatment times. Incubation of 
BMP-2 with heparin derivatives of intermediate sulfation levels resulted in higher 
bioactivity compared to BMP-2 alone only after the longest heat treatment time. Protein 
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interaction with heparin species was indirectly measured by differential scanning 
fluorimetry and showed that Hep and Hep-N could induce conformational changes in a 
model protein, suggesting a specific interaction between these heparin species and 
protein. This study demonstrated that small changes to the sulfation level of heparin will 
continue to allow direct interaction with proteins, but desulfation could have large 
effects on the protective features of heparin.  
 The development of tissue engineering techniques to improve tendon-bone 
integration after tendon reattachment is one approach to treating tendon injury. Another 
is to understand what causes tendon degeneration in order to prevent progression of 
tendinopathy. In Chapter 5, an established overuse protocol was characterized for the 
inbred Dahl Salt Resistant strain of rat. The supraspinatus tendon was analyzed by 
cathepsin zymography and histology at 4 and 8 weeks of overuse. Minor tissue damage 
was observed by 4 weeks, but tissue disorganization was more obvious by 8 weeks of 
overuse and was localized at the insertion region of the tendon. Cathepsin zymography 
revealed higher cathepsin L activity in the insertion region of the tendon of overused 
shoulders compared to non-running controls at both 4 and 8 weeks. These findings 
validated the use of the Dahl Salt Resistant rat for developing a supraspinatus tendon 
overuse injury in an area that experiences the most tendon tears. Furthermore, these 
results revealed a potential new mechanism for tendon degeneration caused by overuse. 
 
6.2 Conclusions 
 The research presented in this dissertation advances understanding of the role of 
sulfation in developing heparin-based biomaterials and provides insight into a novel, 
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potential mechanism of tissue degradation in tendon overuse.  The results of these 
studies suggest that heparin 1) interacts with charged soluble factors to enhance 
paracrine signaling and 2) its sulfation level can affect the protection conferred to 
growth factors in a denaturing environment. Furthermore, the characterization of the in 
vivo overuse model was critical in establishing baseline tissue damage and identifying 
cathepsin activity within overused tendon.  
The numerous docking sites for protein on heparin [30, 339] was used as an 
opportunity to develop covalently crosslinked heparin-containing hydrogels to enhance 
dynamic soluble factor treatment of MSCs. Heparin, with its multiple carboxyl groups, 
is amenable to methacrylamide (MAm)-group functionalization that allows for the 
formation of a covalent crosslinked network. Heparin addition to hydrogels have been 
shown to control the release of proteins (Supplemental figure A.1) [231, 232], but its use 
for sequestering multiple soluble factors from a defined coculture environment is 
relatively unexplored.  
In Chapter 3, a coculture experiment was described to allow dynamic signaling 
between encapsulated MSCs and monolayers of osteoblasts. The presence of members 
of the BMP family is likely in this coculture system since it has been established that 
osteoblasts can secrete BMP-2, BMP-4, and BMP-7, which are known to induce 
osteogenesis in MSCs [273, 274]. Cocultures were compared to the cocultures of 
encapsulated MSCs with monolayers of MSCs and all data were expressed as a 
difference between the values of cell-laden hydrogels and acellular hydrogels of the 
same polymer composition cultured in parallel. Effects of osteoblast coculture on ALP 
activity were apparent by day 1, and MSCs encapsulated in 10% wt. heparin 
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methacrylamide (MAm) hydrogels showed the largest time-dependent increase in ALP 
activity by 21 days with a 5-fold increase over day 1 (Figure 3.5a). While all cell-laden 
hydrogels accumulated calcium over 21 days, the 10% wt. heparin MAm samples 
cocultured with osteoblasts showed an over 50-fold increase in calcium content from 
day 14 and were significantly higher than MSC coculture controls on the same day 
(Figure 3.5b). All samples cocultured with osteoblasts showed significantly higher 
calcium accumulation by 21 days compared to samples cocultured with MSCs. Results 
of elevated ALP activity and calcium accumulation observed in samples cocultured with 
osteoblasts suggests that heparin interacted with osteoblast-secreted factors to mediate 
MSC-directed ALP production and mineralization not seen in controls. Previous 
research has shown that specific BMP interaction with heparin results in the 
augmentation of the biological activity of BMPs, as reflected in the production of 
mineralized tissue or induction of osteoblastic differentiation of MSCs [34, 249, 275], 
which makes these hydrogel formulations particularly suited to enhancing pro-
osteogenic signaling from nearby cells.  
The differences in mineralization patterns between hydrogels cocultured with 
osteoblasts suggested that heparin may prevent uniform pre-treatment of cells in a bulk 
hydrogel containing 10% wt. heparin MAm (Figure 3.6). It was observed that the 
presence of heparin reduced diffusion of positively-charged molecules, such as the 
model protein histone, into the hydrogel, particularly into the 10% wt. heparin MAm 
formulation (Figure 3.7). This phenomenon was not observed when hydrogels were 
allowed to absorb the similarly sized, negatively-charged protein casein. Protein 
transport is limited by molecular size and by charge interactions between proteins and 
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extracellular matrix (ECM) molecules [285]. An in vivo study showed that the presence 
of heparan sulfate in the ECM could decrease the effective diffusion coefficient of 
polyanion-binding lactoferrin through tissues by ~60%, indicating that the effective 
charge of heparin can affect the diffusion of charged molecules in our system [286]. To 
prevent non-uniform treatment of cells, the heparin-containing hydrogels would either 
have to be reduced in geometry, include less heparin, or include heparin that has lower 
affinity for proteins. Selective desulfation of heparin can modulate its affinity to proteins 
[340] with the addition of reducing the anti-coagulation activity [290, 340] for in vivo 
translation.  
Chapter 4 highlights the selective desulfation of heparin to produce Hep-N, Hep-
N,-6O, and Hep-, with minimal change to overall chain length (Figure 4.1). Non-
glycosylated BMP-2 was very heat unstable, exhibiting a bioactivity level ~34% after a 
2min exposure to heat (Figure 4.4). The thermal stress of heating at 65°C appeared to 
cause non-reversible unfolding as bioactivity was not recovered after removal from heat. 
Addition of native heparin at 100 molar excess to BMP-2 prior to heating was shown to 
maintain BMP-2 bioactivity at ~68% over 15min of thermal stress compared to ~0.1% 
of BMP-2-alone. Complexes of 10:1 heparin:BMP-2 were a significant improvement in 
maintaining BMP-2 bioactivity over free BMP-2, but exhibited significantly lower 
bioactivity than 100:1 after 15min of heat treatment (Figure 4.4). 
An excess of heparin was chosen in order to ensure BMP-heparin interaction. 
These approximate molar ratio of heparin to protein have also been used in a previous 
study investigating heparin with FGF-2 [303] and a delivery vehicle that has shown 
modulated release with 100:1 heparin:growth factor concentrations [304]. It has been 
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estimated that 5-6 molecules of BMP-2 can be bound to each heparin chain [168], so 
there were heparin molecules that were not saturated with BMP in these studies. It is 
possible that the excess of unoccupied heparin at 100 molar excess may play additional 
roles in slowing denaturation of BMP-2.  
All the desulfated derivatives at 100 molar excess failed to be as effective as 
100:1 Hep:BMP-2 at maintaining BMP-2 bioactivity when exposed to heat. While the 
overall sulfation of Hep-N is approximately 82% of native heparin, the bioactivity of 
BMP-2 with Hep-N after 2min of heating, which may represent moderate thermal stress, 
is approximately 30% of untreated BMP-2. Incubation of Hep-N or Hep-N,-6O with BMP-
2 prior to 15min of heating resulted in similar bioactivity levels, which was significantly 
lower than 100:1 Hep:BMP-2 but significantly higher than BMP-2 alone and BMP-2 
incubated with Hep-. These results indicate that overall sulfation is not the only factor in 
maintaining BMP-2 stability as relatively small changes to sulfation can significantly 
affect the maintenance of BMP-2 bioactivity. However, Hep-N and Hep-N,-6O may retain 
sufficient sulfation to protect growth factors in denaturing environments. Differential 
scanning fluorimetry (Figure 4.6) and circular dichroism (Supplementary figure A.2) 
data show that Hep and Hep-N produce conformation changes in histone, indicating that 
these heparin species can directly complex to protein. Furthermore, N-desulfated heparin 
has been shown to be amenable to osteogenic differentiation [219] and exhibits reduced 
anti-coagulation activity [290], indicating that this heparin derivative shows beneficial 
features as a biomaterial.  
Characterization of a relevant tendon overuse animal model was presented in 
Chapter 5. The inbred Dahl Salt Resistant strain of rat was subjected to up to 8 weeks of 
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downhill running and the supraspinatus tendons were analyzed by histology and 
cathepsin zymography. Histological scoring demonstrated that collagen disorganization 
and increased rounding of cells was apparent after 8 weeks of downhill running at the 
insertion region compared to controls (Table 5.1), and demonstrated that increased 
period of overuse caused accumulation of damage. The increased observations of 
rounded cells is similar to what has been shown in outbred rats subjected to downhill 
running, in which repeated passing through the acromion can cause the tendon to exhibit 
a compression-induced, cartilaginous phenotype [99, 115]. Comparisons between the 
insertion regions of the 8-week group under circular polarized microscopy showed 
differences in crimping pattern (Figure 5.2). While the control tendons demonstrated 
tightly packed fibers with periodic and cohesive crimping, the insertion of the overused 
tendons exhibited regions of flattened crimps and a loss of the periodicity of crimping. 
These changes may indicate collagen disruption due to overuse [341].     
Samples from the insertion region of overused tendon at both time points 
consistently showed active cathepsin L bands between 25-35kDa that were 1.8-fold 
higher in activity than controls (Figure 5.3a, d). Furthermore, there was evidence of high 
molecular weight bands (50-75kDa) from the insertion regions of 4 week overuse 
tendons, which were attributed to cathepsin K bound to extracellular matrix, as seen in 
osteoclasts in previous studies [342]. Evidence of active cathepsins in tendon overuse 
had not been previously demonstrated and may represent a novel mechanism for tendon 
degeneration.  
Cathepsins are potent proteases that can play major roles in initiating fibrillar 
collagen degradation or destabilizing the collagen network [139, 343]. They have been 
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described in orthopaedic cell types such as synovial fibroblasts that become activated 
during rheumatoid arthritis, inducing the degradation of aggrecan and type I and II 
collagen [344-346]. While inflammatory environments have been shown to directly 
induce cathepsin secretion [347], it was demonstrated that mechanical stress could 
upregulate the expression of cathepsin B in chondrocytes [348]. Tendon overuse caused 
an early increase in cathepsin K activity, suggesting that it may play a role in initiating 
fibrillar collagen degradation, making it easier for other collagenases to sustain the 
degradation [139]. A sustained increased activity of cathepsin L over the 8-week 
running period indicates that protein digestion remains elevated over time, leading to 
accumulated collagen degradation.   
 
6.3 Future Directions 
The findings in this dissertation provide significant insight to understanding 
tendon overuse in a physiologically relevant animal model and to the development of 
heparin-based biomaterials for coculture applications and growth factor delivery. The 
goal of Specific Aim I and II was to develop techniques that can be used to improve 
tendon to bone integration through the use of heparin-based materials. The results of 
those studies contribute fundamental concepts about the effects of heparin sulfation on 
hydrogel properties and protective effects against protein denaturation. In Aim III, the 
tendon overuse model was characterized in order to establish an inbred strain of rat for 
this overuse protocol for future cellular therapies and to better understand tendon 
degeneration prior to tendon rupture. The studies highlighted above serve as a 
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foundation for future studies that use GAG-based biomaterials to slow the progression of 
tendon degeneration or improve the fixation of tendon to bone after rupture.  
Future work can expand on the research presented here in order to improve 
tendon to bone integration after tendon rupture and to develop therapeutics to prevent 
tendon degeneration. Hydrogels of heparin derivatives can aid in pre-treating cells prior 
to implantation. The study of soluble heparin derivatives with BMP-2 provided insight 
on the effect of sulfation level on maintaining growth factor bioactivity. Hep-N, Hep-N,-6O, 
and Hep- can be chemically modified to allow covalent crosslinking into hydrogels such 
that the differing levels of  sulfation can be presented in 3D. These hydrogels may 
improve the coculture technique presented in Chapter 3 by allowing more uniform 
distribution of soluble factors and a more uniform cell response. Since selective 
desulfation may affect the GAG backbone, it would be interesting to see if desulfated 
heparin derivatives affect cell response in coculture. Desulfated chondroitin sulfate, 
chondroitin, was able to enhance the chondrogenic response of encapsulated MSCs in 
comparison to chondroitin sulfate when treated with chondrogenic medium, possibly by 
decreasing the affinity of the growth factor to the scaffold to allow growth factor 
induced signaling [349].  
Development of a natural enthesis or insertion between tendon and bone remains 
a goal after tendon reattachment surgeries. While allowing some mineralization on a 
reattached tendon may quickly improve the strength of integration between tendon and 
bone, too much ectopic mineralization may cause other complications that may resemble 
calcific tendinopathy [350, 351]. Another approach to bridging the tendon to bone 
interface is by delivering cocultured cells within GAG-based hydrogels into the interface 
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region. The delivered cells would ideally form a fibrochondrocytic phenotype that 
transitions from tendon into bone. The desired cell type will determine the type of GAG-
based hydrogel to use in coculture. In order to stabilize the fibrocartilage phenotype [17, 
350], hydrogels of chondroitin-4-sulfate may be conducive for cell maintenance [218]. 
In Chapter 3, MSCS were cocultured with osteoblasts, but MSCs may be cocultured 
with other cell types such as tenocytes that may provide the necessary cues to bridge the 
tendon to bone gap [352, 353].  
The spatial organization of MSCs during coculture can affect differentiation 
capacity of MSCs. Chondrogenic differentiation of MSCs can be improved when 
cultured as aggregates [354]. In order to use this cell culture environment, desulfated 
heparin species can be developed into microspheres and incorporated into cell spheroids. 
Microspheres may be used to sequester growth factors from the cell culture medium or 
from neighboring cells. This alternative format avoids the potential diffusional 
limitations due to the bulk heparin hydrogels and can be amenable to delivery to the 
tendon-bone interface.      
In lieu of cellular delivery, delivery of bioactive factors such as BMPs from 
heparin-containing hydrogels may help direct endogenous cell responses [21, 50]. With 
a library of desulfated heparin derivatives, delivery systems can be developed with 
varying affinity for proteins, thereby controlling their release. Heparin-containing 
hydrogels can also bind multiple growth factors for delivery, which may improve the 
biological outcome in complex tissues. By being able to control the spatiotemporal 
release of soluble factors through biomaterial selection and design of the scaffold, 
control over molecules such as mitogens, growth factors, and morphogens, may more 
! 117 
closely replicate biological processes [355, 356]. In another biomaterial approach, 
polyelectrolyte multilayers can be formed from sequential physisorption of anionic and 
cantionic polymers and do not require harmful processing of the material, allowing 
growth factor incorporation between layers [357]. Inclusion of heparin species as the 
anionic layer in polyelectrolyte multilayers can help protect growth factors such as BMP 
from loss of bioactivity while also controlling the release of BMP [358]. Furthermore, 
these materials are conformal, allowing delivery with scaffolds of complex geometry 
[359]. These polyelectrolyte multilayers have been shown to induce tissue integration 
and recruit progenitor cells to a cell free scaffold [359], suggesting that these materials 
may be amenable for study at the tendon-bone interface.  
Increase in cathepsin activity within overused tendon is a novel finding for this 
animal model and is a promising target for therapeutics. Currently, we are collecting 
human tendon samples that are typically discarded after debridement or supraspinatus 
tendon reattachment procedures to determine if differences in cathepsin activity are 
related to the chronicity of the tendon injury. Preliminary results show that active 
cathepsins exists within torn supraspinatus tendon, but more samples will be analyzed 
and cross-referenced with type of tear (acute versus chronic), gender, and age to better 
understand the profile of cathepsin activity. If increased cathepsin activity is a 
significant feature in human rotator cuff tears, the animal model will prove extremely 
useful in testing whether cathepsin inhibition can affect the progression of tendon 
degeneration.  
Cathepsins have been found to have interesting interactions with 
glycosaminoglycans; studies have shown that GAGs may contribute to the inhibition or 
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activation of cathepsins. Chondroitin sulfate and heparin have been purported to aid in 
activating pro-cathepsn B and L by helping to destabilize the inhibitory peptide 
sequence [133, 360-362]. However, these studies utilized tissue-derived cathepsins, 
which may have contained other cathepsins as contaminants. In a more recent study, 
cathepsin L and B were shown to be inhibited in the presence of chondroitin sulfate 
[363]. Dissimilarly, chondroitin sulfate formed highly active complexes with cathepsin 
K to degrade collagen. Furthermore, incubation of cathepsin K with heparin sulfate or 
heparin inhibited its activity. In light of these results, the use of heparin-based materials 
may prove advantageous in inhibiting the activities of specific cathepsins where they are 
expressed in vivo. How heparin and desulfated heparin species modulate the activity of 
cathepsin L and K will need to be evaluated, but the design of materials that can affect 
the autocatalysis of cathepsins is an exciting prospect.  
Active cathepsins are inhibited by the constitutively secreted cystatins, but 
deficiencies in cystatins may cause excessive tissue damage [364]. Administration of 
cystatin C can determine if extracellular cathepsin activity is a prominent feature of 
tendon overuse. Cystatin C is positively-charged at physiological pH and in a 
preliminary study, its release was modulated by encapsulating the inhibitor within 
heparin-containing hydrogels (Supplementary figure A.4). If cathepsin L activity is 
determined to be located within the lysosomes, intracellular inhibitors such as E64 may 
be used to evaluate the effect of cathepsin inhibition [365].   
Determination of the role and timescale of cathepsin activity within tendon 
overuse can be a significant advancement in preventing and treating tendon diseases. 
Cathepsin K activity was detected early and cathepsin L showed sustained activity over 
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time within our animal model. If cathepsin expression can be reliably detected at 
different (early to chronic) stages of tendon degeneration, diagnostic probes can be 
developed to help detect tendons that may be susceptible to rupture. Currently, partial 
tears in tendon are difficult to detect with diagnostic imaging [366, 367]. The advent of 
fluorescent or near infrared probes for specific enzymes within tissues may help detect 
early tendinopathic changes. A near infrared probe that remained quenched in its native 
state, but became fluorescent upon enzyme cleavage was detected in femtomole 
quantities by fluorescence-mediated tomography [368]. A similar probe was used to 
detect active cathepsin K, and was able to show the location of cathepsin K near 
macrophages where elastin damage was evident [369]. Early diagnosis of tendinopathy 
can help identify and implement conservative treatments that prevent progression of the 
tendon degeneration.    
The benefits of having a consistent tendon overuse animal model allows us to 
adjust therapeutic parameters in order to best address the tendon degeneration. Heparin 
is just one GAG in a family of many, including chondroitin sulfate, dermatan sulfate, 
keratan sulfate and hyaluronan [181]. Hyaluronan, a non-sulfated GAG, has received 
attention in the field of biomaterials for being able to bind to the cell surface receptor 
CD44, exhibiting a relatively fast turnover rate, and participating in wound healing and 
inflammation [370-372]. The studies presented in this thesis have shown the importance 
of sulfation level on heparin, but this concept of understanding how molecular changes 
affect cell and protein interaction can be extended to many of the above materials. 
Sulfation position and presentation of GAG can have significant effects on cell 
responses. Both chondroitin-6-sulfate (C-6-S) and chondroitin-4-sulfate (C-4-S) were 
! 120 
able to promote wound closure in a 2D wound model, but only C-4-S promoted wound 
contraction in a 3D wound model [373], suggesting that fibroblasts can sense sulfation 
level differences as well as presentation of GAG.  
The research presented in this thesis contributes significant concepts for the 
development of future heparin-based biomaterials and exciting opportunities to test 
therapeutics in an in vivo tendon overuse model. Heparin-derived materials have 
attractive biological features that can be engineered to be safe in vivo and efficacious for 
growth factor delivery. Culturing MSCs in heparin-containing hydrogels is a valuable 
technique for controlling the presentation of soluble factors to encapsulated cells and has 
potential for efficiently pre-treating a large population of cells. Selective desulfation of 
heparin enables studies on the effect of sulfation on protein interaction. In this thesis, it 
was shown that the level of sulfation on heparin can affect the bioactivity of BMP-2 in 
denaturing conditions. This will affect the choice of heparin species for biomaterial 
development. Finally, an inbred animal model for tendon overuse was characterized, 
featuring a novel potential mechanism of tissue degradation that may become a future 
therapeutic target. Overall, the research presented here provides the framework for 
developing GAG-based materials that take into consideration molecular interactions 
with proteins in order to develop the most efficacious delivery system for cells and 
growth factors. Furthermore, characterization of an in vivo overuse injury provides a test 








A.1 Release of Platelet-Derived Growth Factor-BB From Heparin-Containing 
Hydrogels 
A.1.1 Materials and Methods 
A.1.1.1 Encapsulation of platelet-derived growth factor-BB 
 Recombinant rat platelet-derived growth factor-BB (PDGF-BB, R&D Systems) 
was resuspended as a working stock solution of 50µg/mL. Heparin MAm synthesis and 
hydrogel parameters are described in detail in Chapter 3. PDGF-BB was mixed into the 
macromer solution prior to photoinitiated crosslinking. After polymerization, hydrogels 
were placed in PBS and the entire supernatant was collected on days 1, 3, 5, 7, and 9. A 
rat PDGF-BB Immunoassay Kit (R&D Systems) was used to detect the amount of 
PDGF-BB released. A theoretical initial amount of 69.4ng of PDGF-BB was 
encapsulated within each hydrogel, representing a 1:1,000 molar ratio of PDGF-BB to 
heparin in the 10% heparin MAm hydrogels.     
A.1.1.2 Statistical Analysis  
 A two-way analysis of variance (ANOVA) was used to determine statistical 
differences of groups and subsequent one-way ANOVAs were used to determine 
differences across time for each hydrogel type and differences across hydrogel type for 





 PDGF-BB was released in a burst from 0% heparin MAm hydrogels, showing no 
significant difference in cumulative PDGF-BB amount between timepoints (Figure A.1). 
The PDGF-BB released from 1% heparin MAm hydrogels on day 1 was significantly 
lower than the cumulative values at all other timepoints. Release of PDGF-BB from 
10% heparin MAm hydrogels was very low on day 1 and showed no significant 
differences across time. At day 1, the amount of PDGF-BB released from 0%, 1%, and 
10% heparin MAm hydrogels were significantly different from each other. At all other 
timepoints thereafter, only the cumulative amount from 10% heparin MAm hydrogels 
was significantly lower than the amounts from 0% and 1% heparin MAm hydrogels. 
 
 
Figure A.1 Heparin-containing hydrogels can control release of positively-charged 
PDGF-BB. Increasing amounts of heparin from 1% to 10% within the hydrogel 
drastically reduced the amount of growth factor released into solution. While 0% 
heparin MAm hydrogels exhibited a burst release with no subsequent release, 1% 
heparin MAm hydrogels showed a lower burst release with subsequent release. 
Hydrogels of 10% heparin MAm appeared to prevent release of PDGF-BB. n=3±s.d., 
* indicates significantly higher PDGF release from 0% heparin MAm hydrogels than 
from 1% and 10% heparin MAm hydrogels, # indicates significantly less release of 
PDGF from 10% heparin MAm hydrogels compared to 0% and 1% heparin MAm 
hydrogels.  
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A.2 Heparin-Induced Secondary Structure Changes in Histone  
A.2.1 Materials and Methods 
Ultraviolet circular dichroism (CD) spectra were recorded on an OLIS DSM 17 
CD spectrophotometer with OLIS 14 CD software. The sample chamber was maintained 
at 20°C and spectra were collected over 190-260nm from a demountable quartz cuvette 
(Starna) with a pathlength of 0.5mm.  
Lysine-rich H1 histone (Sigma-Aldrich) and heparin derivatives (Hep, Hep-N, 
Hep-N,-6O, Hep-) were reconstituted at 1mg/mL in 1% v/v 1X PBS in ddH2O. Different 
concentrations of heparin derivatives were evaluated to minimize deviations from 
baseline spectra. Spectra of individual components and mixtures were recorded at final 
concentrations of 100µg/mL histone and 5µg/mL heparin derivatives. Spectra were 
smoothed by least squares fit and were translated such that the millidegree reading was 0 
at 260nm. Results are expressed as an average of 10 readings as molar ellipticity with 
units in deg * cm2/dmol. 
A.2.2 Results 
A concentration of 5µg/mL of heparin species worked well for Hep, Hep-N, and 
Hep-N,-6O. The same concentration for Hep- produced a signal that may have affected the 
spectra collected as a mixture with histone, so was not included in these results. Histone 
protein displays a predominant random coil configuration with a minimum between 200-
205nm (Figure A.2). When Hep or Hep-N was incubated with histone, an obvious 
positive shift in the spectra was observed. When Hep-N,-6O was incubated with histone, 
no such shift was observed. 
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These results suggest that Hep or Hep-N can interact with histone to induce a 
change in in its peptide bond configuration, or secondary structure. The shift may signal 
a loss in random coil amount, but it is currently unclear how these shifts affect 
corresponding amounts or configurations of α-helices or β-sheets within histone. 
Addition of Hep-N,-6O does not seem to induce a large change in secondary structure 








Figure A.2 Far UV CD spectra of histone-alone and in mixtures containing heparin 
derivatives. Addition of Hep or Hep-N shifted the spectra of histone, suggesting a 
change in secondary structure due to these ligands. Addition of Hep-N,-6O did not 
produce the same shift.    
! 125 
A.3 Interactions of Soluble Histone:Heparin Complexes with Heparin-
Containing Hydrogels 
A.3.1 Materials and Methods 
A.3.1.1 Characterization of histone:heparin complexes and hydrogels 
A range of histone:heparin mass ratio were formulated in order to identify 
soluble complexes. Histone and heparin stock solutions were made at 1mg/mL in 1X 
PBS. Mixtures were pipetted into clear 96-well plates and the absorbance at 420nm was 
recorded.  
Hydrogels (90% wt H2O) of 0%, 10%, or 100% heparin MAm were fabricated 
with the remaining amount composed of poly(ethylene glycol)-diacrylate (MW~3,400). 
After crosslinking by ammonium persulfate and TEMED, hydrogels were allowed to 
swell overnight and weighed. Thereafter, the hydrogels were lyophilized and weighed 
once more. The swelling ratio was calculated as the ration between the swollen hydrogel 
weight and the lyophilized hydrogel weight.   
A.3.1.2 Pull-in study 
For pull-in studies, a complex ratio of 35 molar excess of heparin to histone was 
chosen. After 0%, 10%, and 100% heparin MAm hydrogels were fabricated, they were 
placed in a histone or complex solution containing fluorescein-tagged histone for 24 
hours. Then hydrogels were imaged by confocal microscopy (n≥3) and the average 
fluorescence across the depth for each hydrogel group was computed. Representative 
images and graphs of fluorescence values are shown up to half the hydrogel depth, as 
fluorescence attenuation was apparent with greater depths.   
A.3.1.3 Hydrogel supernatant analysis 
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The supernatants from pull-in studies were analyzed for remaining heparin and 
protein in solution. The complex solutions were analyzed for heparin by DMMB and 
protein was assayed by BCA. Histone-only solutions were analyzed by BCA assay.  
A.3.1.4 Statistical Analysis  
Max fluorescence in hydrogels after histone or complex pull-in was analyzed by 
t-test within each hydrogel formulation. Data from supernatants were analyzed by one-
way ANOVA. All data were analyzed with a significance level of p≤0.05. 
A.3.2 Results and Discussion 
A large range of soluble complexes could be formed, with turbidity appearing 
only in the region around where histone and heparin concentrations were equivalent 
(Figure A.3.1a). The experiments in this study utilized concentrations of heparin and 
histone that fell within the heparin-rich zones. Heparin-containing hydrogels could be 
formed without significant changes to the swelling ratio (Figure A.3.1b), indicating that 
differences observed in diffusion could be attributed to differences in relative charge 
within the hydrogel.  
 
Figure A.3.1 Characterization of complexes and hydrogels. (a) Turbidity measurement 
of different concentration ratio of heparin and histone. (b) Swelling ratio of hydrogels. 
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From analysis of the remaining supernatant, no significant differences in heparin 
concentration were observed between the different hydrogel types (Figure A.3.3a), 
suggesting that complexed histone did not have appreciable affinity to the different 
hydrogel formulations. However, the protein assay revealed that less complexed histone 
remained in the supernatant when 100% heparin MAm hydrogels were incubated in it 
(Figure A.3.3b), suggesting some pull-in of complexes into these hydrogels. These 
results suggest that complexes may decomplex as histone is sequestered into the 100% 
heparin MAm hydrogels while heparin remains in the supernatant.  
Histone and complexes were relatively well distributed across the depth of a 
hydrogel containing 0% heparin MAm (Figure A.3.2). However, when hydrogels 
contained 10% heparin MAm, the maximum intensity of histone was 1.9 times higher 
than complexes within the same hydrogel formulation (p≤0.05) and the histone-only 
!
Figure A.3.2 Analysis of supernatants from pull-in study. (a) Remaining heparin in 
solution after pull-in study incubation showed no significant differences across the 
different hydrogel types. (b) BCA analysis showed that less histone remained in 
solution when incubated with 100% heparin MAm hydrogels, yet more remained 
when histone was complexed to heparin. n=3±s.d., * indicates significantly higher 
than histone remaining from incubation with 100% heparin MAm hydrogels, # 
indicates significantly higher than complexed histone incubated with 100% heparin 
MAm hydrogels, and + indicates significantly higher than histone incubated in 10% 
heparin MAm hydrogels (p≤0.05). 
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samples appeared to distribute primarily to the surfaces of the hydrogels. This lack of 
accumulation of complexed histone in the 10% heparin MAm hydrogels suggests that 
the complex has less affinity for heparin MAm, in contrast to results for free histone. 
The maximum intensity of the complex was not significantly different from histone 
pulled into 100% heparin MAm hydrogels, although the distribution appeared broader. 
The similar distribution of free and complexed histone in the 100% heparin MAm 
hydrogels may indicate instability of the complexes such that at high heparin MAm 
concentrations, competition may occur between soluble and immobilized heparin. This 




Figure A.3.3 Distribution of fluorescently-tagged histone and complexes of histone 
after pull-in in hydrogels of increasing amounts of heparin MAm. (a) Distribution of 
histone and complexes in 0% heparin MAm hydrogel show no differences in peak 
fluorescence or overall distribution. (b) Histone appears to distribute primarily to the 
surfaces of the hydrogel and its peak fluorescence is higher than complexed histone in 
10% heparin MAm hydrogels. (c) High peak fluorescence was observed for both 
histone and complexed histone. n=3±s.d., * indicates significant difference in peak 
fluorescence between histone and complexed histone.    
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A.4 Release of Cystatin C from a Heparin-Containing Hydrogel 
A.4.1 Materials and Methods 
A.4.1.1 Hydrogel Fabrication 
  Oligo(polyethylene glycol) fumarate 10K  and poly(ethylene glycol)-diacrylate 
3.4K were used as a mixture of 50:50 by weight. Heparin MAm was incorporated in 
amounts of 0% and 50% weight of total dry weight of polymer and subsequently 
dissolved in PBS with 0.018M ammonium persulfate/N, N, N', N'-
tetramethylethylenediamine for an initial water content of 90% (w/w). Macromer 
solutions were dispensed in 30 µL amounts into PTFE (Teflon) wells and allowed to 
crosslink for 10 minutes at 37°C. Resulting hydrogel disks were 6 mm in diameter and 
~1 mm thick.  
A.4.1.2 Cystatin C Release from Hydrogels  
Hydrogels were fabricated and allowed to swell overnight in PBS in wells of a 
48-well plate. Hydrogels were subsequently lyophilized for a day to remove all liquid in 
the samples. Following lyophilization, each hydrogel was incubated with 15µL of 
6.7ng/µL cystatin C at 4°C for 1 day to allow protein absorption into the hydrogel. The 
next day, 300µL of PBS with 1% BSA was added to each well and immediately 
collected for the day 0 time point. The supernatant was replenished and the procedure of 
collecting and replenishing the supernatant was repeated every day for up to 5 days.     
The cystatin C in supernatants was detected by Western blot. Samples, control, 
and ladder were loaded into a 12.5% polyacrylamide SDS-PAGE gel and run at 200V. 
Protein bands were transferred from the gel to a nitrocellulose membrane by 
electroblotting with a semi-dry method. The membrane was blocked with Odyssey 
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blocking buffer and incubated with primary rabbit polyclonal cystatin C antibody 
overnight at 4°C. The membranes were washed and incubated with 1:5000 dilution of 
fluorescent secondary anti-rabbit antibody for 1 hour. Blots were imaged and image files 
were processed with Adobe Photoshop and analyzed with ImageJ. Results are shown as 
mean ± standard deviation. Statistical significance was determined using a 2-sample t-
test, p≤0.05.        
A.4.2 Results 
Cystatin C release occurred in a burst release from both 0% and 50% heparin 
hydrogels on day 1. However, significantly lower amounts of cystatin was cumulatively 





Figure A.4 Release of cystatin C over 5 days from hydrogels. Crosslinking 50% wt. 
heparin MAm into the hydrogel can significantly reduce the release of cystatin C over 
5 days. * indicate that 0% heparin hydrogels released more cystatin than 50% heparin 
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